Positive	O
and	O
negative	O
regulation	O
of	O
the	O
composite	B-DNA
octamer	I-DNA
motif	I-DNA
of	O
the	O
interleukin	B-DNA
2	I-DNA
enhancer	I-DNA
by	O
AP-1	B-protein
,	O
Oct-2	B-protein
,	O
and	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
.	O

The	O
differentiating	O
agent	O
retinoic	O
acid	O
(	O
RA	O
)	O
has	O
been	O
previously	O
reported	O
to	O
interfere	O
with	O
12-O-tetradecanoyl-phorbol-13-acetate	O
(	O
TPA	O
)	O
/Ca	O
(	O
2+	O
)	O
-induced	O
signals	O
for	O
the	O
regulation	O
of	O
the	O
-96	B-DNA
to	I-DNA
-66-bp	I-DNA
octamer	I-DNA
motif	I-DNA
found	O
in	O
the	O
enhancer	O
for	O
the	O
interleukin	B-DNA
(	I-DNA
IL	I-DNA
)	I-DNA
-2	I-DNA
gene	I-DNA
,	O
which	O
encodes	O
a	O
major	O
T	B-protein
lymphocyte	I-protein
growth	I-protein
factor	I-protein
.	O

The	O
IL-2	B-DNA
octamer	I-DNA
motif	I-DNA
is	O
a	O
composite	O
cis-element	B-DNA
which	O
binds	O
Oct-1	B-protein
and	O
Oct-2	B-protein
as	O
well	O
as	O
a	O
TPA/Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-inducible	I-protein
nuclear	I-protein
factor	I-protein
,	O
previously	O
termed	O
octamer-associated	B-protein
protein	I-protein
(	O
OAP40	B-protein
)	O
.	O

We	O
show	O
here	O
that	O
Oct-2	B-protein
,	O
despite	O
the	O
presence	O
of	O
an	O
active	O
transcriptional	O
activation	O
domain	O
,	O
requires	O
TPA/Ca	O
(	O
2+	O
)	O
-induced	O
signals	O
to	O
strongly	O
transactivate	O
the	O
IL-2	B-DNA
octamer	I-DNA
motif	I-DNA
in	O
Jurkat	O
T	O
cells	O
.	O

This	O
Oct-2	B-protein
-dependent	O
transactivation	O
is	O
inhibited	O
by	O
RA	O
.	O

The	O
presence	O
of	O
an	O
intact	B-protein
COOH-terminal	I-protein
domain	I-protein
of	O
Oct-2	B-protein
contributes	O
to	O
both	O
TPA/Ca	O
(	O
2+	O
)	O
-induced	O
transactivation	O
and	O
the	O
RA-mediated	O
repression	O
.	O

We	O
also	O
show	O
that	O
both	O
Fos	B-protein
and	O
Jun	B-protein
components	O
of	O
the	O
AP-1	B-protein
factors	O
participate	O
in	O
the	O
OAP40	B-protein
complex	I-protein
.	O

Furthermore	O
,	O
transfected	O
c-jun	B-DNA
,	I-DNA
jun-B	I-DNA
,	I-DNA
jun-D	I-DNA
,	I-DNA
c-fos	I-DNA
,	I-DNA
or	I-DNA
Fos-B	I-DNA
expression	I-DNA
vectors	I-DNA
partially	O
substitute	O
for	O
TPA	O
and	O
Ca2+	O
and	O
cooperate	O
with	O
Oct-2	B-protein
for	O
the	O
transactivation	O
of	O
the	O
combined	O
OAP/octamer	B-DNA
cis-element	I-DNA
.	O

Mutations	O
of	O
the	O
genuine	B-DNA
octamer-binding	I-DNA
site	I-DNA
abrogate	O
both	O
the	O
binding	O
of	O
Oct-1	B-protein
and	O
Oct-2	B-protein
and	O
the	O
TPA/Ca	O
(	O
2+	O
)	O
-induced	O
transactivation	O
of	O
the	O
OAP/octamer	B-DNA
motif	I-DNA
.	O

OAP	B-protein
confers	O
to	O
Oct-2	B-protein
responsivity	O
to	O
both	O
TPA/Ca2+	O
and	O
RA	O
,	O
since	O
specific	O
mutations	O
of	O
the	O
AP-1/OAP-binding	B-DNA
site	I-DNA
significantly	O
reduce	O
the	O
transactivation	O
by	O
Oct-2	B-protein
in	O
response	O
to	O
TPA	O
and	O
Ca2+	O
and	O
abolish	O
the	O
inhibition	O
by	O
RA	O
.	O

Furthermore	O
,	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
(	O
RAR	B-protein
)	O
alpha	O
is	O
able	O
to	O
inhibit	O
in	O
vitro	O
the	O
formation	O
of	O
the	O
complex	O
between	O
the	O
nuclear	O
AP-1	B-protein
/OAP	B-protein
and	O
its	O
specific	O
binding	O
site	O
,	O
resulting	O
in	O
the	O
interference	O
with	O
Oct-2	B-protein
-dependent	O
cis-regulatory	O
function	O
of	O
this	O
AP-1	B-protein
element	O
.	O

Therefore	O
,	O
we	O
propose	O
that	O
the	O
TPA/calcium-activated	O
AP-1	B-protein
/OAP	B-protein
element	O
is	O
the	O
main	O
target	O
of	O
positive	O
or	O
negative	O
regulatory	O
signals	O
influencing	O
the	O
IL-2	B-DNA
octamer	I-DNA
motif	I-DNA
,	O
through	O
synergism	O
with	O
Oct-2	B-protein
and	O
antagonism	O
by	O
RAR	B-protein
.	O

Positive	NULL
and	NULL
Negative	NULL
Regulation	NULL
of	NULL
the	NULL
Composite	NULL
Octamer	NULL
Motif	NULL
of	NULL
the	NULL
Interleukin	NULL
2	NULL
Enhancer	NULL
by	NULL
AP-1	NULL
,	NULL
OCT-2	NULL
,	NULL
and	NULL
Retinoic	NULL
Acid	NULL
Receptor	NULL
By	NULL
Ugo	NULL
de	NULL
Grazia	NULL
,	NULL
f	NULL
!	NULL

l	NULL
Maria	NULL
Pia	NULL
Felli	NULL
,	NULL
*	NULL
Alessandra	NULL
Vacca	NULL
,	NULL
Antonietta	NULL
R.	NULL
Farina	NULL
,	NULL
``	NULL
Marella	NULL
§	NULL
Lucia	NULL
Cappabianca	NULL
,	NULL
*	NULL
Daniela	NULL
Meco	NULL
,	NULL
t	NULL
Monica	NULL
Farina	NULL
,	NULL
?	NULL

Isabella	NULL
Screpanti	NULL
,	NULL
t	NULL
Luigi	NULL
Frati	NULL
,	NULL
t	NULL
!	NULL

l	NULL
and	NULL
Alberto	NULL
Gulinot*	NULL
From	NULL
the	NULL
*Department	NULL
of	NULL
Experimental	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
L'Aquila	NULL
,	NULL
67100	NULL
1'Aquila	NULL
;	NULL
tDepartment	NULL
of	NULL
Experimental	NULL
Medicine	NULL
,	NULL
University	NULL
La	NULL
Sapienza	NULL
,	NULL
00161	NULL
Rome	NULL
;	NULL
Genoa	NULL
National	NULL
Institute	NULL
for	NULL
Cancer	NULL
Research	NULL
,	NULL
Biotechnology	NULL
Section	NULL
,	NULL
00161	NULL
Rome	NULL
;	NULL
and	NULL
Istituto	NULL
Mediterraneo	NULL
di	NULL
Neuroscienze	NULL
,	NULL
86077	NULL
Pozzilli	NULL
,	NULL
Italy	NULL
Summary	NULL
The	NULL
differentiating	NULL
agent	NULL
retinoic	NULL
acid	NULL
(	NULL
RA	NULL
)	NULL
has	NULL
been	NULL
previously	NULL
reported	NULL
to	NULL
interfere	NULL
with	NULL
12-O-tetradecanoyl-phorbol-13-acetate	NULL
-induced	NULL
signals	NULL
for	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
-96	NULL
to	NULL
-66-bp	NULL
octamer	NULL
motif	NULL
found	NULL
in	NULL
the	NULL
enhancer	NULL
for	NULL
the	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-2	NULL
gene	NULL
,	NULL
which	NULL
encodes	NULL
a	NULL
major	NULL
T	NULL
lymphocyte	NULL
growth	NULL
factor	NULL
.	NULL

The	NULL
IL-2	NULL
octamer	NULL
motif	NULL
is	NULL
a	NULL
composite	NULL
cis-element	NULL
which	NULL
binds	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
as	NULL
well	NULL
as	NULL
a	NULL
TPA/Ca*+-inducible	NULL
nuclear	NULL
factor	NULL
,	NULL
previously	NULL
termed	NULL
octamer-associated	NULL
protein	NULL
(	NULL
OAP®	NULL
)	NULL
.	NULL

We	NULL
show	NULL
here	NULL
that	NULL
Oct-2	NULL
,	NULL
despite	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
active	NULL
transcriptional	NULL
activation	NULL
domain	NULL
,	NULL
requires	NULL
TPA/Ca**-induced	NULL
signals	NULL
to	NULL
strongly	NULL
transactivate	NULL
the	NULL
IL-2	NULL
octamer	NULL
motif	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

This	NULL
Oct-2-dependent	NULL
transactivation	NULL
is	NULL
inhibited	NULL
by	NULL
RA	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
an	NULL
intact	NULL
COOH-terminal	NULL
domain	NULL
of	NULL
Oct-2	NULL
contributes	NULL
to	NULL
both	NULL
TPA/Ca'*-induced	NULL
transactivation	NULL
and	NULL
the	NULL
RA-mediated	NULL
repression	NULL
.	NULL

We	NULL
also	NULL
show	NULL
that	NULL
both	NULL
Fos	NULL
and	NULL
Jun	NULL
components	NULL
of	NULL
the	NULL
AP-1	NULL
factors	NULL
participate	NULL
in	NULL
the	NULL
OAP	NULL
complex	NULL
.	NULL

Furthermore	NULL
,	NULL
transfected	NULL
c-jun	NULL
,	NULL
jun-B	NULL
,	NULL
jun-D	NULL
,	NULL
c-fos	NULL
,	NULL
or	NULL
Fos-B	NULL
expression	NULL
vectors	NULL
partially	NULL
substitute	NULL
for	NULL
TPA	NULL
and	NULL
Ca	NULL
``	NULL
+*	NULL
and	NULL
cooperate	NULL
with	NULL
Oct-2	NULL
for	NULL
the	NULL
transactivation	NULL
of	NULL
the	NULL
combined	NULL
OAP/octamer	NULL
cis-element	NULL
.	NULL

Mutations	NULL
of	NULL
the	NULL
genuine	NULL
octamer-binding	NULL
site	NULL
abrogate	NULL
both	NULL
the	NULL
binding	NULL
of	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
and	NULL
the	NULL
TPA/Ca**	NULL
-induced	NULL
transactivation	NULL
of	NULL
the	NULL
OAP/octamer	NULL
motif	NULL
,	NULL
OAP	NULL
confers	NULL
to	NULL
Oct-2	NULL
responsivity	NULL
to	NULL
both	NULL
TPA/Ca®*	NULL
and	NULL
RA	NULL
,	NULL
since	NULL
specific	NULL
mutations	NULL
of	NULL
the	NULL
AP-1/OAP-binding	NULL
site	NULL
significantly	NULL
reduce	NULL
the	NULL
transactivation	NULL
by	NULL
Oct-2	NULL
in	NULL
response	NULL
to	NULL
TPA	NULL
and	NULL
Ca**	NULL
and	NULL
abolish	NULL
the	NULL
inhibition	NULL
by	NULL
RA	NULL
.	NULL

Furthermore	NULL
,	NULL
retinoic	NULL
acid	NULL
receptor	NULL
(	NULL
RAR	NULL
)	NULL
&	NULL
is	NULL
able	NULL
to	NULL
inhibit	NULL
in	NULL
vitro	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
complex	NULL
between	NULL
the	NULL
nuclear	NULL
AP-1/OAP	NULL
and	NULL
its	NULL
specific	NULL
binding	NULL
site	NULL
,	NULL
resulting	NULL
in	NULL
the	NULL
interference	NULL
with	NULL
Oct-2-dependent	NULL
cis-regulatory	NULL
function	NULL
of	NULL
this	NULL
AP-1	NULL
element	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
propose	NULL
that	NULL
the	NULL
TPA/calcium-activated	NULL
AP-1/OAP	NULL
element	NULL
is	NULL
the	NULL
main	NULL
target	NULL
of	NULL
positive	NULL
or	NULL
negative	NULL
regulatory	NULL
signals	NULL
influencing	NULL
the	NULL
IL-2	NULL
octamer	NULL
motif	NULL
,	NULL
through	NULL
synergism	NULL
with	NULL
Oct-2	NULL
and	NULL
antagonism	NULL
by	NULL
RAR	NULL
.	NULL

etinoic	NULL
acid	NULL
(	NULL
RA	NULL
)	NULL
!	NULL

exerts	NULL
a	NULL
wide	NULL
variety	NULL
of	NULL
effects	NULL
on	NULL
embryonic	NULL
development	NULL
,	NULL
cell	NULL
differentiation	NULL
,	NULL
and	NULL
growth	NULL
through	NULL
regulation	NULL
of	NULL
growth	NULL
factors	NULL
and	NULL
homeotic	NULL
genes	NULL
and	NULL
protooncogenes	NULL
(	NULL
1-7	NULL
)	NULL
.	NULL

Retinoids	NULL
bind	NULL
to	NULL
several	NULL
receptors	NULL
1	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
;	NULL
GR	NULL
,	NULL
glucocorticoid	NULL
receptor	NULL
;	NULL
NFAT	NULL
,	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
;	NULL
PKC	NULL
,	NULL
protein	NULL
kinase	NULL
C	NULL
;	NULL
RA	NULL
,	NULL
retinoic	NULL
acid	NULL
;	NULL
RAR	NULL
,	NULL
retinoic	NULL
acid	NULL
receptor	NULL
;	NULL
RARE-3	NULL
,	NULL
RAR-responsive	NULL
element	NULL
of	NULL
the	NULL
RAR	NULL
(	NULL
3	NULL
promoter	NULL
;	NULL
RRL	NULL
,	NULL
rabbit	NULL
reticulocyte	NULL
lysate	NULL
;	NULL
RXR	NULL
,	NULL
retinoid	NULL
X	NULL
receptor	NULL
;	NULL
tk	NULL
,	NULL
thymidine	NULL
kinase	NULL
;	NULL
TPA	NULL
,	NULL
12-O-tetradecanoyl-phorbol-13-acetate	NULL
.	NULL

(	NULL
e.g	NULL
.	NULL

,	NULL
retinoic	NULL
acid	NULL
receptors	NULL
[	NULL
RAR	NULL
]	NULL
x	NULL
,	NULL
B	NULL
,	NULL
and	NULL
y	NULL
and	NULL
retinoid	NULL
X	NULL
receptor	NULL
[	NULL
RXR	NULL
]	NULL
ax	NULL
,	NULL
3	NULL
,	NULL
and	NULL
y	NULL
and	NULL
their	NULL
isoforms	NULL
)	NULL
,	NULL
which	NULL
combine	NULL
with	NULL
each	NULL
other	NULL
to	NULL
form	NULL
a	NULL
variety	NULL
of	NULL
dimers	NULL
able	NULL
to	NULL
bind	NULL
and	NULL
transactivate	NULL
specific	NULL
cis-elements	NULL
of	NULL
target	NULL
genes	NULL
(	NULL
for	NULL
review	NULL
see	NULL
reference	NULL
8	NULL
)	NULL
.	NULL

The	NULL
range	NULL
of	NULL
genes	NULL
controlled	NULL
by	NULL
retinoids	NULL
is	NULL
further	NULL
broadened	NULL
by	NULL
the	NULL
ability	NULL
of	NULL
RAR	NULL
and	NULL
RXR	NULL
to	NULL
control	NULL
the	NULL
expression	NULL
of	NULL
genes	NULL
encoding	NULL
other	NULL
transacting	NULL
factors	NULL
,	NULL
such	NULL
as	NULL
the	NULL
homeotic	NULL
Hox	NULL
genes	NULL
,	NULL
nuclear	NULL
pro-tooncogenes	NULL
,	NULL
and	NULL
the	NULL
development-related	NULL
octamer-binding	NULL
proteins	NULL
(	NULL
1	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
9-12	NULL
)	NULL
.	NULL

This	NULL
latter	NULL
class	NULL
of	NULL
proteins	NULL
belongs	NULL
to	NULL
the	NULL
POU	NULL
family	NULL
of	NULL
transacting	NULL
factors	NULL
characterized	NULL
by	NULL
a	NULL
homeodomain	NULL
DNA-binding	NULL
region	NULL
(	NULL
13	NULL
,	NULL
14	NULL
)	NULL
.	NULL

Transcrip-	NULL
1485	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

©	NULL
The	NULL
Rockefeller	NULL
University	NULL
Press	NULL
«	NULL
0022-1007/94/10/1485/13	NULL
$	NULL
2.00	NULL
Volume	NULL
180	NULL
October	NULL
1994	NULL
1485-1497	NULL
tional	NULL
regulation	NULL
by	NULL
RAR	NULL
and	NULL
other	NULL
nuclear	NULL
receptors	NULL
also	NULL
occurs	NULL
through	NULL
antagonism	NULL
or	NULL
synergism	NULL
with	NULL
distinct	NULL
families	NULL
of	NULL
transacting	NULL
factors	NULL
,	NULL
including	NULL
AP-1	NULL
(	NULL
15-21	NULL
;	NULL
for	NULL
review	NULL
see	NULL
reference	NULL
22	NULL
)	NULL
.	NULL

The	NULL
influence	NULL
of	NULL
RAR	NULL
on	NULL
lymphoid	NULL
T	NULL
cell	NULL
differentiation	NULL
and	NULL
growth	NULL
is	NULL
suggested	NULL
by	NULL
the	NULL
ability	NULL
of	NULL
RA	NULL
to	NULL
modulate	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
human	NULL
and	NULL
murine	NULL
IL-2	NULL
genes	NULL
,	NULL
which	NULL
encode	NULL
a	NULL
major	NULL
T	NULL
lymphocyte	NULL
growth	NULL
factor	NULL
(	NULL
23	NULL
,	NULL
24	NULL
)	NULL
involved	NULL
in	NULL
the	NULL
control	NULL
of	NULL
T	NULL
cell	NULL
development	NULL
(	NULL
25	NULL
,	NULL
26	NULL
)	NULL
.	NULL

The	NULL
use	NULL
of	NULL
retinoids	NULL
as	NULL
therapeutic	NULL
agents	NULL
and	NULL
the	NULL
subsequent	NULL
potential	NULL
immunosuppression	NULL
and	NULL
influence	NULL
on	NULL
development	NULL
underline	NULL
the	NULL
importance	NULL
of	NULL
elucidating	NULL
their	NULL
regulatory	NULL
role	NULL
in	NULL
the	NULL
IL-2	NULL
gene	NULL
.	NULL

The	NULL
IL-2	NULL
promoter	NULL
contains	NULL
several	NULL
control	NULL
elements	NULL
,	NULL
which	NULL
mainly	NULL
require	NULL
a	NULL
variety	NULL
of	NULL
transacting	NULL
factors	NULL
activated	NULL
by	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
and	NULL
calcium-mediated	NULL
signals	NULL
(	NULL
for	NULL
reviews	NULL
see	NULL
references	NULL
27	NULL
and	NULL
28	NULL
)	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
reported	NULL
that	NULL
one	NULL
target	NULL
of	NULL
the	NULL
RAR-mediated	NULL
inhibition	NULL
of	NULL
the	NULL
PKC-and	NULL
calcium-mediated	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer	NULL
is	NULL
an	NULL
octamer	NULL
motif	NULL
at	NULL
a	NULL
position	NULL
-96	NULL
to	NULL
-66	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
start	NULL
site	NULL
(	NULL
23	NULL
)	NULL
.	NULL

This	NULL
motif	NULL
binds	NULL
the	NULL
inducible	NULL
nuclear	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
OAP®	NULL
,	NULL
whose	NULL
composition	NULL
includes	NULL
jun	NULL
protein	NULL
(	NULL
29	NULL
,	NULL
30	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
both	NULL
Oct-1-	NULL
and	NULL
Oct-2-transacting	NULL
factors	NULL
(	NULL
29	NULL
,	NULL
31	NULL
,	NULL
32	NULL
)	NULL
,	NULL
which	NULL
are	NULL
,	NULL
therefore	NULL
,	NULL
potential	NULL
targets	NULL
of	NULL
RA-mediated	NULL
regulation	NULL
.	NULL

Whereas	NULL
Oct-1	NULL
is	NULL
ubiquitous	NULL
,	NULL
Oct-2	NULL
has	NULL
a	NULL
more	NULL
restricted	NULL
pattern	NULL
of	NULL
cell	NULL
distribution	NULL
,	NULL
being	NULL
expressed	NULL
in	NULL
B	NULL
cells	NULL
and	NULL
in	NULL
some	NULL
T	NULL
cells	NULL
(	NULL
31	NULL
,	NULL
32	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
both	NULL
transacting	NULL
factors	NULL
are	NULL
regulated	NULL
by	NULL
stimuli	NULL
that	NULL
activate	NULL
the	NULL
IL-2	NULL
gene	NULL
(	NULL
29	NULL
,	NULL
31	NULL
,	NULL
32	NULL
)	NULL
.	NULL

Specifically	NULL
,	NULL
Oct-2	NULL
levels	NULL
are	NULL
upregulated	NULL
by	NULL
antigen	NULL
stimulation	NULL
in	NULL
some	NULL
T	NULL
cells	NULL
(	NULL
32	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
distinct	NULL
Oct	NULL
factors	NULL
regulating	NULL
cytokine	NULL
gene	NULL
expression	NULL
suggests	NULL
that	NULL
they	NULL
might	NULL
be	NULL
responsive	NULL
to	NULL
differential	NULL
regulatory	NULL
pathways	NULL
.	NULL

Indeed	NULL
,	NULL
distinct	NULL
transcriptional	NULL
requirements	NULL
for	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
have	NULL
been	NULL
reported	NULL
.	NULL

Whereas	NULL
Oct-1	NULL
is	NULL
competent	NULL
in	NULL
enhancing	NULL
transcription	NULL
from	NULL
snRNA	NULL
promoters	NULL
,	NULL
it	NULL
requires	NULL
supplementation	NULL
by	NULL
auxiliary	NULL
factors	NULL
,	NULL
which	NULL
provide	NULL
transcriptional	NULL
activation	NULL
domains	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
the	NULL
herpes	NULL
virus	NULL
VP16	NULL
protein	NULL
harbors	NULL
a	NULL
strong	NULL
acidic	NULL
transactivation	NULL
domain	NULL
)	NULL
to	NULL
activate	NULL
mRNA	NULL
promoters	NULL
(	NULL
13	NULL
,	NULL
33	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
Oct-2	NULL
harbors	NULL
a	NULL
strong	NULL
COOH-terminal	NULL
transcriptional	NULL
activation	NULL
domain	NULL
for	NULL
mRNA	NULL
promoters	NULL
,	NULL
which	NULL
when	NULL
replacing	NULL
the	NULL
Oct-1	NULL
COOH	NULL
terminus	NULL
,	NULL
can	NULL
provide	NULL
transcriptional	NULL
activation	NULL
(	NULL
13	NULL
,	NULL
34	NULL
)	NULL
.	NULL

The	NULL
OAP®	NULL
complex	NULL
may	NULL
represent	NULL
auxiliary	NULL
factors	NULL
required	NULL
for	NULL
Oct-1	NULL
function	NULL
.	NULL

However	NULL
,	NULL
the	NULL
requirements	NULL
of	NULL
Oct-2	NULL
for	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
remain	NULL
to	NULL
be	NULL
elucidated	NULL
.	NULL

In	NULL
this	NULL
study	NULL
we	NULL
have	NULL
addressed	NULL
the	NULL
molecular	NULL
events	NULL
implicated	NULL
in	NULL
the	NULL
Oct-2-dependent	NULL
activation	NULL
and	NULL
RA-induced	NULL
downregulation	NULL
of	NULL
the	NULL
octamer	NULL
motif	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer	NULL
.	NULL

We	NULL
show	NULL
that	NULL
the	NULL
IL-2	NULL
octamer	NULL
motif	NULL
is	NULL
a	NULL
composite	NULL
binding	NULL
site	NULL
for	NULL
Oct-2	NULL
and	NULL
a	NULL
fos-	NULL
and	NULL
jun-containing	NULL
AP-1	NULL
complex	NULL
,	NULL
whose	NULL
functional	NULL
cooperation	NULL
is	NULL
required	NULL
to	NULL
fully	NULL
enhance	NULL
transcription	NULL
.	NULL

RARa	NULL
«	NULL
is	NULL
able	NULL
to	NULL
inhibit	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
AP-1-DNA	NULL
complex	NULL
in	NULL
vitro	NULL
,	NULL
resulting	NULL
in	NULL
an	NULL
interference	NULL
with	NULL
the	NULL
Oct-2-dependent	NULL
cis-regulatory	NULL
function	NULL
of	NULL
this	NULL
AP-1	NULL
element	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
AP-1	NULL
element	NULL
appears	NULL
to	NULL
be	NULL
the	NULL
main	NULL
target	NULL
for	NULL
positive	NULL
or	NULL
negative	NULL
regulatory	NULL
signals	NULL
that	NULL
influence	NULL
1486	NULL
the	NULL
IL-2	NULL
octamer	NULL
motif	NULL
,	NULL
either	NULL
through	NULL
cooperation	NULL
with	NULL
Oct-2	NULL
or	NULL
antagonism	NULL
by	NULL
RAR	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Plasmid	NULL
Constructs	NULL
'The	NULL
plasmid	NULL
pILZCAT	NULL
contains	NULL
the	NULL
IL	NULL
2-flanking	NULL
region	NULL
from	NULL
-575	NULL
to	NULL
+47	NULL
bp	NULL
driving	NULL
the	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
gene	NULL
(	NULL
35	NULL
)	NULL
.	NULL

All	NULL
reporter	NULL
constructions	NULL
based	NULL
on	NULL
the	NULL
pBLCAT2	NULL
vector	NULL
were	NULL
prepared	NULL
by	NULL
use	NULL
of	NULL
a	NULL
vector	NULL
in	NULL
which	NULL
the	NULL
AP-1	NULL
site	NULL
in	NULL
the	NULL
plasmid	NULL
backbone	NULL
had	NULL
been	NULL
deleted	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
17	NULL
)	NULL
.	NULL

IL-2-0AP/OCT-tk-CAT	NULL
was	NULL
constructed	NULL
by	NULL
inserting	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
proximal	NULL
(	NULL
-96	NULL
to	NULL
-66-bp	NULL
)	NULL
IL-2	NULL
octamer	NULL
motif	NULL
into	NULL
either	NULL
the	NULL
pBLCAT2	NULL
vector	NULL
(	NULL
36	NULL
)	NULL
(	NULL
including	NULL
the	NULL
octamerless	NULL
[	NULL
-105-bp	NULL
]	NULL
thymidine	NULL
kinase	NULL
[	NULL
tk	NULL
]	NULL
promoter	NULL
driving	NULL
the	NULL
CAT	NULL
gene	NULL
)	NULL
or	NULL
the	NULL
(	NULL
-37-bp	NULL
)	NULL
tk-CAT	NULL
vector	NULL
(	NULL
37	NULL
)	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
23	NULL
)	NULL
.	NULL

All	NULL
of	NULL
the	NULL
plasmids	NULL
containing	NULL
mutated	NULL
(	NULL
m	NULL
)	NULL
or	NULL
deleted	NULL
(	NULL
A	NULL
)	NULL
sequences	NULL
of	NULL
the	NULL
IL-2	NULL
octamer	NULL
motif	NULL
(	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
were	NULL
prepared	NULL
in	NULL
the	NULL
same	NULL
way	NULL
.	NULL

Wild-type	NULL
deletion	NULL
mutants	NULL
and	NULL
chimeric	NULL
forms	NULL
of	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
cDNAs	NULL
,	NULL
cloned	NULL
in	NULL
pCG	NULL
expression	NULL
vector	NULL
containing	NULL
the	NULL
human	NULL
CMV	NULL
promoter	NULL
,	NULL
were	NULL
provided	NULL
by	NULL
Dr.	NULL
W.	NULL
Herr	NULL
(	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
)	NULL
(	NULL
34	NULL
)	NULL
.	NULL

pRcRSV-OCT2	NULL
was	NULL
constructed	NULL
by	NULL
inserting	NULL
the	NULL
Oct-2	NULL
cDNA	NULL
in	NULL
the	NULL
pRcRSV	NULL
vector	NULL
(	NULL
Invitrogen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Expression	NULL
vectors	NULL
encoding	NULL
hRARa	NULL
and	NULL
its	NULL
mutant	NULL
forms	NULL
(	NULL
A1-81	NULL
and	NULL
A81-152	NULL
)	NULL
and	NULL
RXRa	NULL
were	NULL
provided	NULL
by	NULL
Dr.	NULL
P.	NULL
Chambon	NULL
(	NULL
Laboratoire	NULL
de	NULL
Génétique	NULL
Moléculaire	NULL
des	NULL
Eucaryotes	NULL
du	NULL
CNRs	NULL
,	NULL
Strasbourg	NULL
,	NULL
France	NULL
)	NULL
and	NULL
Dr.	NULL
R.	NULL
Evans	NULL
(	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
)	NULL
(	NULL
19	NULL
,	NULL
38	NULL
)	NULL
.	NULL

The	NULL
plasmid	NULL
tkTREp2-CAT	NULL
contains	NULL
the	NULL
RA-responsive	NULL
element	NULL
driving	NULL
the	NULL
CAT	NULL
gene	NULL
through	NULL
the	NULL
tk	NULL
promoter	NULL
(	NULL
39	NULL
)	NULL
.	NULL

pAP-1coll-tk-CAT	NULL
contains	NULL
five	NULL
copies	NULL
of	NULL
the	NULL
collagenase	NULL
AP1	NULL
site	NULL
in	NULL
front	NULL
of	NULL
the	NULL
tk	NULL
promoter	NULL
(	NULL
40	NULL
)	NULL
.	NULL

JMneo	NULL
(	NULL
c-fos	NULL
expression	NULL
vector	NULL
)	NULL
,	NULL
fos-Bneo	NULL
(	NULL
fos-B	NULL
expression	NULL
vector	NULL
)	NULL
,	NULL
their	NULL
control	NULL
vector	NULL
pRAXneo	NULL
,	NULL
and	NULL
expression	NULL
vectors	NULL
for	NULL
c-jun	NULL
and	NULL
jun-B	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
(	NULL
RSV	NULL
)	NULL
promoter	NULL
(	NULL
RSV	NULL
c-jun	NULL
and	NULL
RSV	NULL
jun-B	NULL
)	NULL
and	NULL
their	NULL
control	NULL
vector	NULL
pUC-RSV	NULL
were	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
41-44	NULL
)	NULL
.	NULL

The	NULL
jun-D	NULL
expression	NULL
vector	NULL
,	NULL
containing	NULL
jun-D	NULL
cDNA	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
CMV	NULL
promoter	NULL
in	NULL
the	NULL
pCMV-1	NULL
vector	NULL
,	NULL
has	NULL
been	NULL
previously	NULL
described	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Cell	NULL
Culture	NULL
and	NULL
DNA	NULL
Transfection	NULL
.	NULL

The	NULL
human	NULL
Jurkat	NULL
T	NULL
cell	NULL
lines	NULL
(	NULL
T-77	NULL
clone	NULL
and	NULL
a	NULL
subclone	NULL
partially	NULL
resistant	NULL
to	NULL
RA	NULL
)	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
and	NULL
antibiotics	NULL
(	NULL
50	NULL
IU/ml	NULL
penicillin	NULL
and	NULL
50	NULL
ug/ml	NULL
streptomycin	NULL
;	NULL
Flow	NULL
Laboratories	NULL
,	NULL
Ayrshire	NULL
,	NULL
Scotland	NULL
)	NULL
.	NULL

HeLa	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
DMEM	NULL
(	NULL
Flow	NULL
Laboratories	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
and	NULL
antibiotics	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
30	NULL
ng/ml	NULL
12-O-tetradecanoyl-phorbol-13-acetate	NULL
(	NULL
TPA	NULL
)	NULL
,	NULL
1	NULL
ug/ml	NULL
A23187	NULL
or	NULL
2	NULL
ug/ml	NULL
ionomycin	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
1	NULL
uM	NULL
RA	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
.	NULL

Transfection	NULL
of	NULL
Jurkat	NULL
cells	NULL
were	NULL
carried	NULL
out	NULL
either	NULL
by	NULL
the	NULL
DEAE	NULL
dextran	NULL
method	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
23	NULL
,	NULL
45	NULL
)	NULL
or	NULL
by	NULL
electropora-tion	NULL
.	NULL

In	NULL
the	NULL
latter	NULL
case	NULL
,	NULL
plasmid	NULL
DNA	NULL
mixtures	NULL
were	NULL
,	NULL
added	NULL
to	NULL
10	NULL
``	NULL
Jurkat	NULL
cells/ml	NULL
medium	NULL
without	NULL
serum	NULL
and	NULL
antibiotics	NULL
and	NULL
elec-troporated	NULL
in	NULL
a	NULL
gene	NULL
pulser	NULL
apparatus	NULL
(	NULL
Bio-Rad	NULL
Laboratories	NULL
,	NULL
Rich-mond	NULL
,	NULL
CA	NULL
)	NULL
using	NULL
350	NULL
V	NULL
and	NULL
960	NULL
F	NULL
capacitance	NULL
,	NULL
and	NULL
then	NULL
further	NULL
cultured	NULL
in	NULL
complete	NULL
growth	NULL
medium	NULL
.	NULL

All	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
plasmid	NULL
pCH110	NULL
(	NULL
Pharmacia	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
for	NULL
transfection	NULL
efficiency	NULL
.	NULL

24	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
the	NULL
drugs	NULL
indicated	NULL
above	NULL
.	NULL

After	NULL
a	NULL
further	NULL
24	NULL
h	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
protein	NULL
extracts	NULL
were	NULL
prepared	NULL
for	NULL
the	NULL
CAT	NULL
and	NULL
B-galactosidase	NULL
assays	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Data	NULL
were	NULL
quantified	NULL
by	NULL
autoradiography	NULL
and	NULL
liquid	NULL
scintillation	NULL
counting	NULL
and	NULL
normalized	NULL
to	NULL
the	NULL
levels	NULL
of	NULL
3-galactosidase	NULL
expression	NULL
of	NULL
cotrans-	NULL
IL-2	NULL
Octamer	NULL
Regulation	NULL
by	NULL
Ap-1	NULL
,	NULL
Oct-2	NULL
,	NULL
and	NULL
RAR	NULL
fected	NULL
pCH110	NULL
vector	NULL
obtained	NULL
from	NULL
the	NULL
same	NULL
cell	NULL
extract	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
transfected	NULL
Oct	NULL
proteins	NULL
were	NULL
monitored	NULL
by	NULL
gel	NULL
retardation	NULL
assays	NULL
and	NULL
Western	NULL
blotting	NULL
(	NULL
by	NULL
use	NULL
of	NULL
anti-Oct-1	NULL
and	NULL
-Oct-2	NULL
antibodies	NULL
,	NULL
described	NULL
in	NULL
reference	NULL
46	NULL
)	NULL
.	NULL

Nuclear	NULL
Extracts	NULL
.	NULL

-	NULL
Nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
T	NULL
cells	NULL
were	NULL
prepared	NULL
by	NULL
a	NULL
modification	NULL
of	NULL
a	NULL
previously	NULL
described	NULL
technique	NULL
(	NULL
47	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
by	NULL
homogenization	NULL
in	NULL
10	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
10	NULL
mM	NULL
KCl	NULL
,	NULL
1.5	NULL
mM	NULL
MgC	NULL
)	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
1	NULL
mM	NULL
PMSF	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
and	NULL
0.2	NULL
%	NULL
NP-40	NULL
.	NULL

Nuclei	NULL
were	NULL
centrifuged	NULL
at	NULL
1,000	NULL
g	NULL
and	NULL
resuspended	NULL
in	NULL
two	NULL
volumes	NULL
of	NULL
the	NULL
above-described	NULL
solution	NULL
.	NULL

KCl	NULL
was	NULL
added	NULL
to	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
0.39	NULL
M	NULL
,	NULL
and	NULL
nuclei	NULL
were	NULL
extracted	NULL
at	NULL
4°C	NULL
for	NULL
1	NULL
h	NULL
and	NULL
centrifuged	NULL
at	NULL
100,000	NULL
g	NULL
for	NULL
30	NULL
min	NULL
.	NULL

The	NULL
supernatants	NULL
were	NULL
dialyzed	NULL
against	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
50	NULL
mM	NULL
KCI	NULL
,	NULL
1	NULL
mM	NULL
PMSF	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
,	NULL
and	NULL
20	NULL
%	NULL
glycerol	NULL
,	NULL
the	NULL
debris	NULL
removed	NULL
by	NULL
centrifugation	NULL
,	NULL
and	NULL
stored	NULL
at	NULL
-80°C	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
Hela	NULL
cells	NULL
were	NULL
prepared	NULL
by	NULL
homogenizing	NULL
cells	NULL
in	NULL
10	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
;	NULL
10	NULL
mM	NULL
KCl	NULL
,	NULL
0.5	NULL
mM	NULL
PMSF	NULL
,	NULL
and	NULL
0.25	NULL
mM	NULL
DTT	NULL
.	NULL

Nuclear	NULL
fractions	NULL
were	NULL
extracted	NULL
in	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
20	NULL
%	NULL
glycerol	NULL
,	NULL
0.42	NULL
M	NULL
NaC	NULL
)	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
0.25	NULL
mM	NULL
DTT	NULL
,	NULL
and	NULL
0.5	NULL
mM	NULL
PMSF	NULL
,	NULL
dialyzed	NULL
against	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
50	NULL
mM	NULL
KCl	NULL
,	NULL
1	NULL
mM	NULL
PMSF	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
,	NULL
and	NULL
20	NULL
%	NULL
glycerol	NULL
,	NULL
and	NULL
cell	NULL
debris	NULL
were	NULL
removed	NULL
by	NULL
centrifugation	NULL
.	NULL

In	NULL
Vitro	NULL
Translation	NULL
.	NULL

-	NULL
RNA	NULL
templates	NULL
for	NULL
in	NULL
vitro	NULL
translation	NULL
reactions	NULL
of	NULL
hRARa	NULL
,	NULL
hRXRa	NULL
,	NULL
Oct-1	NULL
,	NULL
and	NULL
Oct-2	NULL
were	NULL
generated	NULL
from	NULL
plasmids	NULL
(	NULL
pGEM3	NULL
)	NULL
containing	NULL
the	NULL
cDNAs	NULL
by	NULL
SP6	NULL
polymerase	NULL
(	NULL
Promega	NULL
Biotec	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
and	NULL
translated	NULL
in	NULL
vitro	NULL
with	NULL
rabbit	NULL
reticulocyte	NULL
lysate	NULL
(	NULL
RRL	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
recommendation	NULL
.	NULL

Bacterial	NULL
Expression	NULL
of	NULL
RARa	NULL
Protein	NULL
.	NULL

Full-length	NULL
hRARa	NULL
cDNA	NULL
was	NULL
inserted	NULL
into	NULL
pRSET	NULL
B	NULL
vector	NULL
(	NULL
Invitrogen	NULL
)	NULL
and	NULL
expressed	NULL
in	NULL
Escherichia	NULL
coli	NULL
BL21	NULL
(	NULL
DE3	NULL
)	NULL
plysE	NULL
.	NULL

A	NULL
single	NULL
colony	NULL
of	NULL
E.	NULL
coli	NULL
BL21	NULL
(	NULL
DE3	NULL
)	NULL
plysE	NULL
transformed	NULL
with	NULL
pRSET	NULL
B-RARa	NULL
was	NULL
grown	NULL
in	NULL
Luria	NULL
broth	NULL
with	NULL
ampicillin	NULL
(	NULL
100	NULL
ug/ml	NULL
)	NULL
and	NULL
chloramphenicol	NULL
(	NULL
30	NULL
ug/ml	NULL
)	NULL
at	NULL
37°C	NULL
until	NULL
cell	NULL
density	NULL
reached	NULL
an	NULL
ODsy	NULL
of	NULL
0.7	NULL
.	NULL

Isopropyl	NULL
--	NULL
p	NULL
»	NULL
-thiogalactopyranoside	NULL
(	NULL
IPTG	NULL
;	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
was	NULL
added	NULL
to	NULL
final	NULL
concentration	NULL
0.4	NULL
mM	NULL
for	NULL
3	NULL
h	NULL
to	NULL
induce	NULL
hRARa	NULL
«	NULL
protein	NULL
expression	NULL
.	NULL

Recombinant	NULL
protein	NULL
was	NULL
then	NULL
purified	NULL
on	NULL
resin-charged	NULL
columns	NULL
(	NULL
ProBond	NULL
;	NULL
Invitrogen	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
recommendation	NULL
.	NULL

RARa	NULL
«	NULL
protein	NULL
was	NULL
verified	NULL
by	NULL
Western	NULL
immunoblot	NULL
analysis	NULL
using	NULL
anti-RARa	NULL
«	NULL
primary	NULL
antibody	NULL
Ab9	NULL
(	NULL
hF	NULL
)	NULL
(	NULL
provided	NULL
by	NULL
Dr.	NULL
Chambon	NULL
)	NULL
diluted	NULL
1/1,500	NULL
,	NULL
as	NULL
described	NULL
(	NULL
48	NULL
)	NULL
.	NULL

Electrophoretic	NULL
Mobility	NULL
Shift	NULL
Assay	NULL
.	NULL

-	NULL
P-labeled	NULL
probes	NULL
(	NULL
0.4	NULL
ng	NULL
,	NULL
50,000	NULL
cpm	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
10	NULL
ug	NULL
nuclear	NULL
extracts	NULL
of	NULL
Jurkat	NULL
cells	NULL
for	NULL
20	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
15	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
2.5	NULL
mM	NULL
MgCl	NULL
;	NULL
,	NULL
2	NULL
mM	NULL
DTT	NULL
,	NULL
40	NULL
mM	NULL
KCl	NULL
,	NULL
4	NULL
%	NULL
glycerol	NULL
,	NULL
and	NULL
2-5	NULL
ug	NULL
poly	NULL
(	NULL
dl-dC	NULL
)	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
.	NULL

Anti-pan-fos	NULL
(	NULL
provided	NULL
by	NULL
Dr.	NULL
M.	NULL
Iadarola	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
)	NULL
(	NULL
49	NULL
)	NULL
or	NULL
anti-pan-jun	NULL
antibodies	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
Inc.	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
for	NULL
1.5	NULL
h	NULL
at	NULL
4°C	NULL
after	NULL
binding	NULL
reactions	NULL
,	NULL
described	NULL
above	NULL
.	NULL

In	NULL
other	NULL
experiments	NULL
,	NULL
5	NULL
pg	NULL
Jurkat	NULL
nuclear	NULL
extracts	NULL
and/or	NULL
5	NULL
ul	NULL
in	NULL
vitro	NULL
synthesized	NULL
RAR	NULL
and	NULL
RXRa	NULL
«	NULL
or	NULL
bacterially	NULL
expressed	NULL
RARa	NULL
proteins	NULL
were	NULL
prein-cubated	NULL
with	NULL
1	NULL
ug	NULL
poly	NULL
(	NULL
dl-dC	NULL
)	NULL
in	NULL
10	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
,	NULL
2.5	NULL
mM	NULL
MgCl	NULL
»	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
and	NULL
a	NULL
range	NULL
of	NULL
KCl	NULL
concentrations	NULL
of	NULL
10	NULL
,	NULL
40	NULL
,	NULL
and	NULL
100	NULL
mM	NULL
for	NULL
15	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

After	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
RAR-responsive	NULL
element	NULL
of	NULL
the	NULL
RARRB	NULL
promoter	NULL
(	NULL
RARE	NULL
;	NULL
50	NULL
)	NULL
or	NULL
OAP/OCT	NULL
probe	NULL
,	NULL
the	NULL
reaction	NULL
mixtures	NULL
were	NULL
incubated	NULL
for	NULL
a	NULL
further	NULL
25	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Anti-RARa	NULL
antibody	NULL
Ab9	NULL
&	NULL
(	NULL
hF	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
the	NULL
mixture	NULL
for	NULL
15	NULL
min	NULL
at	NULL
4°C	NULL
after	NULL
the	NULL
binding	NULL
reaction	NULL
.	NULL

All	NULL
binding	NULL
reactions	NULL
were	NULL
per	NULL
1487	NULL
de	NULL
Grazia	NULL
et	NULL
al	NULL
.	NULL

formed	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
20	NULL
ul	NULL
.	NULL

Protein-DNA	NULL
complexes	NULL
were	NULL
separated	NULL
from	NULL
free	NULL
probe	NULL
by	NULL
gel	NULL
electrophoresis	NULL
on	NULL
4	NULL
%	NULL
polyacryl-amide	NULL
gels	NULL
in	NULL
0.25	NULL
x	NULL
TBE	NULL
buffer	NULL
(	NULL
0.23	NULL
M	NULL
Tris-borate	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
pH	NULL
8.0	NULL
)	NULL
at	NULL
150	NULL
V	NULL
for	NULL
1.5	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Gels	NULL
were	NULL
dried	NULL
and	NULL
exposed	NULL
to	NULL
film	NULL
(	NULL
XAR-5	NULL
;	NULL
Eastman-Kodak	NULL
,	NULL
Rochester	NULL
,	NULL
NY	NULL
)	NULL
at	NULL
-80°C	NULL
.	NULL

Results	NULL
TPA	NULL
and	NULL
Calcium	NULL
Ionophore-mediated	NULL
Induction	NULL
of	NULL
Oct-2-dependent	NULL
Activation	NULL
of	NULL
the	NULL
IL-2	NULL
Octamer	NULL
Motif	NULL
and	NULL
Its	NULL
Antagonism	NULL
by	NULL
RA	NULL
.	NULL

Activation	NULL
of	NULL
intact	NULL
(	NULL
-300	NULL
bp	NULL
)	NULL
IL-2	NULL
enhancer	NULL
and	NULL
the	NULL
-96	NULL
to	NULL
-66-bp	NULL
IL-2	NULL
octamer	NULL
motif	NULL
fused	NULL
to	NULL
a	NULL
heterologous	NULL
tk	NULL
promoter	NULL
was	NULL
demonstrated	NULL
in	NULL
Jurkat	NULL
cells	NULL
transfected	NULL
with	NULL
Oct-2	NULL
expression	NULL
vector	NULL
after	NULL
treatment	NULL
with	NULL
TPA	NULL
and	NULL
ionomycin	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Transactivation	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer	NULL
and	NULL
IL-2	NULL
octamer	NULL
motif	NULL
driving	NULL
either	NULL
the	NULL
-105-bp	NULL
tk	NULL
or	NULL
the	NULL
-37-bp	NULL
tk	NULL
promoters	NULL
was	NULL
significantly	NULL
stronger	NULL
in	NULL
Jurkat	NULL
cells	NULL
transfected	NULL
with	NULL
Oct-2	NULL
expression	NULL
vector	NULL
after	NULL
TPA	NULL
and	NULL
ionomycin	NULL
treatment	NULL
than	NULL
that	NULL
caused	NULL
by	NULL
endogenous	NULL
Oct-1	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
empty	NULL
pCG	NULL
vector	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
A	NULL
)	NULL
.	NULL

Accumulation	NULL
of	NULL
nuclear	NULL
Oct-2-IL-2	NULL
octamer	NULL
complex	NULL
could	NULL
be	NULL
demonstrated	NULL
in	NULL
cells	NULL
devoid	NULL
of	NULL
endogenous	NULL
Oct-2	NULL
transfected	NULL
with	NULL
pCG-Oct2	NULL
vector	NULL
,	NULL
which	NULL
encodes	NULL
Oct-2	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
CMV	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
B	NULL
)	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
this	NULL
complex	NULL
were	NULL
augmented	NULL
10-20-fold	NULL
by	NULL
TPA	NULL
and	NULL
ionomycin	NULL
treatment	NULL
due	NULL
to	NULL
upregulation	NULL
of	NULL
the	NULL
CMV	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

This	NULL
drug-induced	NULL
augmentation	NULL
in	NULL
Oct-2	NULL
levels	NULL
alone	NULL
would	NULL
not	NULL
appear	NULL
to	NULL
contribute	NULL
to	NULL
IL-2	NULL
octamer	NULL
motif	NULL
transactivation	NULL
as	NULL
CAT	NULL
activity	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
TPA	NULL
and	NULL
ionomycin	NULL
treatment	NULL
was	NULL
not	NULL
significantly	NULL
increased	NULL
,	NULL
despite	NULL
similar	NULL
levels	NULL
of	NULL
intracellular	NULL
Oct-2	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
B	NULL
and	NULL
C	NULL
;	NULL
compare	NULL
CAT	NULL
activity	NULL
and	NULL
intracellular	NULL
Oct-2	NULL
levels	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
0.2	NULL
ug	NULL
pCG-Oct-2	NULL
and	NULL
treated	NULL
with	NULL
TPA	NULL
/ionomycin	NULL
to	NULL
those	NULL
transfected	NULL
with	NULL
5	NULL
ug	NULL
pCG-Oct-2	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
TPA/	NULL
ionomycin	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
Oct-2	NULL
expression	NULL
vector	NULL
driven	NULL
by	NULL
the	NULL
RSV	NULL
promoter	NULL
(	NULL
RSV-Oct2	NULL
)	NULL
was	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
,	NULL
which	NULL
was	NULL
not	NULL
significantly	NULL
influenced	NULL
by	NULL
TPA/ionomycin	NULL
(	NULL
51	NULL
;	NULL
Fig	NULL
.	NULL

1	NULL
A	NULL
)	NULL
.	NULL

This	NULL
would	NULL
suggest	NULL
a	NULL
requirement	NULL
for	NULL
additional	NULL
TPA	NULL
/ionomycin-induced	NULL
coregulatory	NULL
signals	NULL
in	NULL
Oct-2-mediated	NULL
transactivation	NULL
of	NULL
octamer	NULL
motif	NULL
.	NULL

TPA/ionomycin-induced	NULL
Oct-2-dependent	NULL
transactivation	NULL
of	NULL
both	NULL
the	NULL
intact	NULL
IL-2	NULL
and	NULL
the	NULL
-96	NULL
to	NULL
-66-bp	NULL
IL-2	NULL
octamer	NULL
motif	NULL
was	NULL
significantly	NULL
inhibited	NULL
by	NULL
RA	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
A	NULL
)	NULL
.	NULL

As	NULL
RA	NULL
neither	NULL
inhibited	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
CMV	NULL
promoter	NULL
,	NULL
used	NULL
to	NULL
drive	NULL
Oct-2	NULL
transcription	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
,	NULL
nor	NULL
decreased	NULL
the	NULL
levels	NULL
of	NULL
Oct-2	NULL
protein	NULL
resulting	NULL
from	NULL
transfection	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
D	NULL
)	NULL
,	NULL
the	NULL
inhibitory	NULL
activity	NULL
of	NULL
RA	NULL
likely	NULL
resulted	NULL
from	NULL
interference	NULL
with	NULL
TPA	NULL
/ionomycin-induced	NULL
coregulatory	NULL
signals	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
-96	NULL
to	NULL
-66-bp	NULL
IL-2	NULL
octamer	NULL
motif	NULL
is	NULL
the	NULL
focal	NULL
point	NULL
for	NULL
both	NULL
RA-mediated	NULL
inactivation	NULL
and	NULL
the	NULL
TPA	NULL
/ionomycin-mediated	NULL
cofactor	NULL
requirement	NULL
of	NULL
Oct-2-dependent	NULL
IL-2	NULL
transactivation	NULL
.	NULL

Delineation	NULL
of	NULL
TPA/Ionomycin	NULL
and	NULL
RAR	NULL
responsive	NULL
Domains	NULL
in	NULL
Oct-2	NULL
.	NULL

'To	NULL
study	NULL
the	NULL
domains	NULL
of	NULL
the	NULL
Oct-2	NULL
protein	NULL
that	NULL
are	NULL
involved	NULL
in	NULL
TPA	NULL
/ionomycin-induced	NULL
transactivation	NULL
and	NULL
Figure	NULL
1	NULL
.	NULL

-	NULL
Oct-2	NULL
superinduces	NULL
the	NULL
IL-2	NULL
octamer	NULL
motif	NULL
,	NULL
(	NULL
4	NULL
)	NULL
Graphic	NULL
representation	NULL
of	NULL
the	NULL
fold	NULL
induction	NULL
of	NULL
CAT	NULL
activity	NULL
compared	NULL
with	NULL
basal	NULL
levels	NULL
in	NULL
CAT	NULL
2	NULL
assays	NULL
performed	NULL
on	NULL
cell	NULL
lysates	NULL
prepared	NULL
from	NULL
Jurkat	NULL
cells	NULL
cotransfected	NULL
with	NULL
IL-2-CAT	NULL
(	NULL
row	NULL
1	NULL
)	NULL
,	NULL
OAP/OCT	NULL
(	NULL
-105	NULL
)	NULL
-tk-CAT	NULL
(	NULL
row	NULL
2	NULL
)	NULL
,	NULL
OAP/OCT	NULL
(	NULL
-37	NULL
)	NULL
-tk-CAT	NULL
(	NULL
row	NULL
3	NULL
)	NULL
,	NULL
(	NULL
-105	NULL
)	NULL
-tk-CAT	NULL
(	NULL
row	NULL
4	NULL
)	NULL
,	NULL
or	NULL
(	NULL
-37	NULL
)	NULL
-tk-CAT	NULL
(	NULL
row	NULL
5	NULL
)	NULL
cotransfected	NULL
either	NULL
with	NULL
(	NULL
+	NULL
)	NULL
or	NULL
without	NULL
(	NULL
-	NULL
)	NULL
pCG	NULL
vector	NULL
(	NULL
pCG	NULL
)	NULL
or	NULL
pCG-Oct-2	NULL
expression	NULL
vector	NULL
(	NULL
Oct-2	NULL
)	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
also	NULL
assayed	NULL
in	NULL
cell	NULL
lysates	NULL
prepared	NULL
from	NULL
cells	NULL
cotransfected	NULL
with	NULL
OAP/OCT	NULL
(	NULL
-105	NULL
)	NULL
-tk-CAT	NULL
vector	NULL
and	NULL
either	NULL
pRcRSV	NULL
empty	NULL
vector	NULL
or	NULL
Oct-2	NULL
encoding	NULL
pReRSV-vector	NULL
(	NULL
RSV	NULL
Oct2	NULL
)	NULL
(	NULL
row	NULL
6	NULL
)	NULL
or	NULL
transfected	NULL
with	NULL
CMV-CAT	NULL
alone	NULL
(	NULL
row	NULL
7	NULL
)	NULL
or	NULL
RSV-CAT	NULL
alone	NULL
(	NULL
row	NULL
8	NULL
)	NULL
.	NULL

All	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
the	NULL
above-described	NULL
CAT	NULL
vectors	NULL
plus	NULL
1	NULL
ug	NULL
RARa	NULL
expression	NULL
vector	NULL
.	NULL

Extracts	NULL
m	NULL
,	NULL
in	NULL
all	NULL
cases	NULL
were	NULL
prepared	NULL
24	NULL
h	NULL
after	NULL
<	NULL
treatment	NULL
with	NULL
medium	NULL
alone	NULL
(	NULL
C	NULL
)	NULL
,	NULL
TPA	NULL
and	NULL
ionomycin	NULL
(	NULL
{	NULL
2	NULL
)	NULL
,	NULL
or	NULL
TPA	NULL
and	NULL
ionomycin	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
uM	NULL
All	NULL
treatments	NULL
were	NULL
performed	NULL
24	NULL
h	NULL
after	NULL
transfections	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
mean	NULL
(	NULL
+SE	NULL
from	NULL
three	NULL
to	NULL
six	NULL
experiments	NULL
)	NULL
fold	NULL
induction	NULL
of	NULL
CAT	NULL
activity	NULL
observed	NULL
in	NULL
drug-treated	NULL
versus	NULL
-untreated	NULL
cells	NULL
(	NULL
basal	NULL
)	NULL
.	NULL

Basal	NULL
CAT	NULL
activity	NULL
values	NULL
(	NULL
expressed	NULL
as	NULL
pmol/h/mg	NULL
protein	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Oct-2	NULL
,	NULL
respectively	NULL
,	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
45	NULL
+	NULL
8	NULL
and	NULL
55	NULL
+	NULL
9	NULL
(	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
IL-2-CAT	NULL
)	NULL
;	NULL
120	NULL
+	NULL
15	NULL
and	NULL
190	NULL
+	NULL
30	NULL
(	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
IL2OAP/OCT	NULL
(	NULL
-105	NULL
)	NULL
tk-CAT	NULL
)	NULL
;	NULL
55	NULL
+	NULL
7	NULL
and	NULL
80	NULL
+	NULL
6	NULL
(	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
IL2OAP/OCT	NULL
(	NULL
-37	NULL
)	NULL
tk-CAT	NULL
)	NULL
;	NULL
110	NULL
+	NULL
10	NULL
and	NULL
105	NULL
+	NULL
15	NULL
(	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
-105tk-CAT	NULL
)	NULL
;	NULL
and	NULL
60	NULL
+	NULL
4	NULL
and	NULL
55	NULL
+	NULL
5	NULL
(	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
-37tk-CAT	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Representative	NULL
EMSA	NULL
of	NULL
Oct-2	NULL
octamer	NULL
complexes	NULL
in	NULL
Jurkat	NULL
cell	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
after	NULL
transfection	NULL
with	NULL
increasing	NULL
amounts	NULL
(	NULL
0.2-5	NULL
ug	NULL
)	NULL
of	NULL
pCG-Oct-2	NULL
expression	NULL
vector	NULL
as	NULL
indicated	NULL
and	NULL
incubation	NULL
for	NULL
4	NULL
h	NULL
either	NULL
in	NULL
medium	NULL
alone	NULL
(	NULL
-	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
TPA	NULL
and	NULL
ionomycin	NULL
(	NULL
+	NULL
)	NULL
.	NULL

Binding	NULL
reactions	NULL
contained	NULL
either	NULL
nuclear	NULL
extracts	NULL
,	NULL
in	NULL
vitro	NULL
translated	NULL
Oct-2	NULL
protein	NULL
(	NULL
RR	NULL
L+	NULL
Ocf2	NULL
)	NULL
,	NULL
or	NULL
unprogrammed	NULL
RRL	NULL
and	NULL
P-labeled	NULL
AOAP/OCT	NULL
oligonucleotide	NULL
probe	NULL
ATATGTAAAACATTT	NULL
(	NULL
see	NULL
also	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

Arrows	NULL
indicate	NULL
specific	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
DNA	NULL
complexes	NULL
.	NULL

Results	NULL
shown	NULL
are	NULL
representative	NULL
of	NULL
two	NULL
similar	NULL
experiments	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Graphic	NULL
representation	NULL
of	NULL
CAT	NULL
activity	NULL
assayed	NULL
in	NULL
cell	NULL
extracts	NULL
prepared	NULL
from	NULL
Jurkat	NULL
cells	NULL
,	NULL
cotransfected	NULL
with	NULL
OAP/OCT	NULL
(	NULL
-105	NULL
)	NULL
-tk-CAT	NULL
reporter	NULL
and	NULL
increasing	NULL
amounts	NULL
of	NULL
pCG-Oct-2	NULL
vector	NULL
,	NULL
24	NULL
h	NULL
after	NULL
treatment	NULL
with	NULL
(	NULL
O	NULL
)	NULL
or	NULL
without	NULL
(	NULL
@	NULL
)	NULL
TPA	NULL
and	NULL
ionomycin	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Representative	NULL
EMSA	NULL
showing	NULL
the	NULL
effect	NULL
of	NULL
RA	NULL
on	NULL
octamer	NULL
complexes	NULL
in	NULL
Jurkat	NULL
cell	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
cells	NULL
transfected	NULL
with	NULL
pCG	NULL
vector	NULL
alone	NULL
(	NULL
+pCG	NULL
)	NULL
or	NULL
with	NULL
pCG-Oct-2	NULL
expression	NULL
vector	NULL
(	NULL
+0c¢2	NULL
)	NULL
after	NULL
4	NULL
h	NULL
treatment	NULL
with	NULL
TPA	NULL
and	NULL
ionomycin	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
+	NULL
)	NULL
of	NULL
1	NULL
uM	NULL
RA	NULL
.	NULL

Displacement	NULL
of	NULL
specific	NULL
Oct	NULL
complexes	NULL
by	NULL
a	NULL
50-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
competitor	NULL
AOAP/OCT	NULL
oligonucleotide	NULL
(	NULL
competitor	NULL
+	NULL
)	NULL
is	NULL
also	NULL
shown	NULL
.	NULL

Last	NULL
two	NULL
lanes	NULL
show	NULL
binding	NULL
reactions	NULL
containing	NULL
unprogrammed	NULL
RRL	NULL
or	NULL
in	NULL
vitro	NULL
translated	NULL
Oct-2	NULL
(	NULL
RRL+OCT2	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

A	NULL
P-labeled	NULL
AOAP/OCT	NULL
oligonucleotide	NULL
probe	NULL
was	NULL
used	NULL
.	NULL

A	NULL
pea	NULL
oct2	NULL
1	NULL
)	NULL
IL-2	NULL
CAT	NULL
2	NULL
)	NULL
OaAP/0CT	NULL
(	NULL
-105	NULL
)	NULL
tk-CAT	NULL
3	NULL
)	NULL
oarroct	NULL
(	NULL
-37	NULL
)	NULL
tk-cat	NULL
+	NULL
»	NULL
4	NULL
)	NULL
(	NULL
-105	NULL
)	NULL
tk-CaAT	NULL
5	NULL
)	NULL
(	NULL
-37	NULL
)	NULL
tk-CaAt	NULL
he	NULL
+	NULL
pRcRSV	NULL
RSV-Oct2	NULL
7	NULL
)	NULL
CMV-CAT	NULL
8	NULL
)	NULL
RASv-Cat	NULL
Q	NULL
BASAL	NULL
P3	NULL
TPA+lon	NULL
W	NULL
TPA+lon+RA	NULL
6	NULL
)	NULL
oarroct	NULL
(	NULL
-105	NULL
}	NULL
tk-Cat	NULL
|	NULL
[	NULL
[	NULL
°	NULL
.	NULL

[	NULL
I	NULL
[	NULL
wﬁggummwg	NULL
?	NULL

dqdﬁ	NULL
T	NULL
y	NULL
v	NULL
o	NULL
10	NULL
20	NULL
30	NULL
«	NULL
0	NULL
so	NULL
so	NULL
CAT	NULL
ACTIVITY	NULL
(	NULL
fold	NULL
induction	NULL
versus	NULL
basal	NULL
)	NULL
B	NULL
C	NULL
D	NULL
2	NULL
ug	NULL
5	NULL
ug	NULL
0.2	NULL
ug	NULL
2	NULL
ug	NULL
5	NULL
g	NULL
+0ct2	NULL
pCG/Oct2	NULL
ARL-OCT2	NULL
+0+	NULL
ARL	NULL
RRL	NULL
»	NULL
OCT2	NULL
RA	NULL
++	NULL
+	NULL
ARL	NULL
TPA	NULL
+	NULL
lon	NULL
soul	NULL
.l	NULL
e	NULL
competitor	NULL
+	NULL
{	NULL
Bil	NULL
Me	NULL
17	NULL
1	NULL
TT	NULL
Oct2p	NULL
#	NULL
>	NULL
wb	NULL
to	NULL
it	NULL
Ob	NULL
0	NULL
we	NULL
OAP/OCT-tk-CAT	NULL
-	NULL
activity	NULL
Gang-j	NULL
.	NULL

.	NULL

40	NULL
e	NULL
-	NULL
,	NULL
Oct-2	NULL
vector	NULL
(	NULL
jig	NULL
)	NULL
in	NULL
the	NULL
inhibitory	NULL
activity	NULL
of	NULL
RA	NULL
,	NULL
we	NULL
cotransfected	NULL
several	NULL
constructs	NULL
encoding	NULL
Oct-2	NULL
and	NULL
Oct-1	NULL
proteins	NULL
carrying	NULL
deletions	NULL
in	NULL
the	NULL
or	NULL
COOH-terminal	NULL
regions	NULL
or	NULL
chimeric	NULL
proteins	NULL
together	NULL
with	NULL
the	NULL
IL-2-0AP/OCT-	NULL
(	NULL
-105	NULL
)	NULL
tk-CAT	NULL
reporter	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
expression	NULL
and	NULL
integrity	NULL
of	NULL
these	NULL
transfected	NULL
wild-type	NULL
mutant	NULL
Oct-2	NULL
and	NULL
Oct-2	NULL
proteins	NULL
in	NULL
each	NULL
transfection	NULL
were	NULL
monitored	NULL
by	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
an	NULL
aliquot	NULL
of	NULL
transfected	NULL
cells	NULL
.	NULL

The	NULL
complexes	NULL
observed	NULL
in	NULL
EMSA	NULL
were	NULL
,	NULL
in	NULL
each	NULL
case	NULL
,	NULL
consistent	NULL
with	NULL
expression	NULL
of	NULL
the	NULL
full-length	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
B	NULL
)	NULL
.	NULL

The	NULL
analysis	NULL
of	NULL
the	NULL
transfected	NULL
Oct-2	NULL
and	NULL
Oct-1	NULL
proteins	NULL
by	NULL
EMSA	NULL
showed	NULL
that	NULL
all	NULL
mutant	NULL
or	NULL
chimeric	NULL
proteins	NULL
accumulated	NULL
within	NULL
the	NULL
cells	NULL
to	NULL
comparable	NULL
levels	NULL
under	NULL
1488	NULL
basal	NULL
conditions	NULL
and	NULL
after	NULL
TPA	NULL
/ionomycin	NULL
or	NULL
RA	NULL
treatments	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
B	NULL
)	NULL
.	NULL

Oct	NULL
protein	NULL
levels	NULL
analyzed	NULL
by	NULL
Western	NULL
immunoblotting	NULL
(	NULL
with	NULL
anti-Oct-2	NULL
and	NULL
anti-Oct-1	NULL
antibodies	NULL
;	NULL
46	NULL
)	NULL
corresponded	NULL
to	NULL
those	NULL
determined	NULL
by	NULL
EMSA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Similar	NULL
TPA	NULL
/ionomycin-induced	NULL
transcriptional	NULL
activation	NULL
function	NULL
and	NULL
repression	NULL
by	NULL
RA	NULL
was	NULL
observed	NULL
with	NULL
Oct-2	NULL
proteins	NULL
deleted	NULL
of	NULL
the	NULL
proximal	NULL
(	NULL
94	NULL
amino	NULL
acids	NULL
,	NULL
Oct-2AN1	NULL
)	NULL
or	NULL
distal	NULL
(	NULL
adjacent	NULL
glutamine-rich	NULL
62	NULL
amino	NULL
acids	NULL
,	NULL
Oct-2AN2	NULL
)	NULL
NHz-terminal	NULL
regions	NULL
compared	NULL
with	NULL
the	NULL
wild-type	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
A	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
deletion	NULL
of	NULL
the	NULL
COOH	NULL
terminus	NULL
from	NULL
residue	NULL
358	NULL
to	NULL
the	NULL
end	NULL
(	NULL
including	NULL
a	NULL
putative	NULL
leucine	NULL
zipper	NULL
;	NULL
Oct-2AC	NULL
)	NULL
decreased	NULL
the	NULL
transacting	NULL
function	NULL
(	NULL
as	NULL
evaluated	NULL
by	NULL
transfec-	NULL
IL-2	NULL
Octamer	NULL
Regulation	NULL
by	NULL
Ap-1	NULL
,	NULL
Oct-2	NULL
,	NULL
and	NULL
RAR	NULL
A	NULL
TPACa	NULL
**	NULL
Transfected	NULL
expression	NULL
r-	NULL
<	NULL
--	NULL
vector	NULL
B	NULL
a	NULL
a	NULL
al	NULL
-	NULL
RA	NULL
+	NULL
RA	NULL
Oct	NULL
1	NULL
cay	NULL
-	NULL
|	NULL
1	NULL
1	NULL
oct	NULL
1AN	NULL
cuv	NULL
I	NULL
``	NULL
--	NULL
|	NULL
1	NULL
1	NULL
Oct	NULL
1Ac	NULL
cuy	NULL
1	NULL
3	NULL
1	NULL
Oct	NULL
2	NULL
cay	NULL
C	NULL
eee	NULL
z	NULL
32	NULL
5	NULL
Oct	NULL
2AN1	NULL
cuy	NULL
C	NULL
9.5	NULL
23	NULL
5	NULL
Oct	NULL
2ANn2	NULL
cuy	NULL
C-	NULL
Cee	NULL
9.5	NULL
20	NULL
3	NULL
oct	NULL
2	NULL
AC	NULL
cuy	NULL
1	NULL
A	NULL
s	NULL
Oct	NULL
2.1.1	NULL
cuy	NULL
1	NULL
1	NULL
1	NULL
Oct	NULL
1.2.1	NULL
cuy	NULL
eom	NULL
?	NULL

?	NULL

?	NULL
)	NULL

G	NULL
1	NULL
1	NULL
Oct	NULL
1.1.2	NULL
cuy	NULL
-	NULL
1	NULL
10	NULL
2	NULL
Oct	NULL
1.2.2	NULL
cuy	NULL
U	NULL
1	NULL
Oct	NULL
2.1.2	NULL
cuy	NULL
G	NULL
25	NULL
3	NULL
Oct	NULL
2.2.1	NULL
cuy	NULL
C	NULL
--	NULL
RZ	NULL
722A	NULL
q	NULL
M	NULL
q	NULL
pCa	NULL
CMY	NULL
1	NULL
3	NULL
1	NULL
IL2-OAP/OCT-tk-CAT	NULL
-	NULL
activation	NULL
(	NULL
fold	NULL
Increase	NULL
)	NULL
B	NULL
5	NULL
g	NULL
z	NULL
q	NULL
L	NULL
4	NULL
44	NULL
.	NULL

ag	NULL
wou	NULL
w	NULL
a	NULL
ot	NULL
to	NULL
tog	NULL
nos	NULL
Transfected	NULL
8	NULL
8	NULL
8	NULL
8	NULL
8	NULL
8	NULL
8	NULL
a	NULL
c	NULL
<	NULL
@	NULL
a	NULL
vector	NULL
“	NULL
Uhuuﬂuuuﬂﬂuq—cu	NULL
1	NULL
8	NULL
b	NULL
*	NULL
``	NULL
w	NULL
|	NULL
u	NULL
if	NULL
bi	NULL
1	NULL
UW	NULL
|	NULL
aoc	NULL
2	NULL
mdakdt	NULL
cs	NULL
a	NULL
Figure	NULL
2	NULL
.	NULL

Differential	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
octamer	NULL
motif	NULL
by	NULL
wild-type	NULL
,	NULL
mutant	NULL
,	NULL
and	NULL
chimeric	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
proteins	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Jurkat	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
5	NULL
ug	NULL
IL2-OAP/OCT	NULL
(	NULL
-105	NULL
)	NULL
tk-CAT	NULL
,	NULL
1	NULL
ug	NULL
RARa	NULL
«	NULL
,	NULL
and	NULL
1	NULL
ug	NULL
of	NULL
either	NULL
the	NULL
wild-type	NULL
,	NULL
mutant	NULL
,	NULL
or	NULL
chimeric	NULL
forms	NULL
of	NULL
the	NULL
two	NULL
Oct	NULL
proteins	NULL
,	NULL
depicted	NULL
on	NULL
the	NULL
left	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
TPA	NULL
and	NULL
ionomycin	NULL
and	NULL
processed	NULL
for	NULL
CAT	NULL
assay	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

CAT	NULL
activities	NULL
relative	NULL
to	NULL
untreated	NULL
(	NULL
basal	NULL
)	NULL
cells	NULL
transfected	NULL
with	NULL
pCG	NULL
vector	NULL
are	NULL
represented	NULL
.	NULL

Basal	NULL
levels	NULL
in	NULL
pCG-transfected	NULL
cells	NULL
were	NULL
100	NULL
+	NULL
15	NULL
pmol/h/mg	NULL
protein	NULL
.	NULL

CAT	NULL
activities	NULL
were	NULL
normalized	NULL
to	NULL
the	NULL
levels	NULL
of	NULL
transfected	NULL
Oct	NULL
proteins	NULL
(	NULL
considering	NULL
the	NULL
ratio	NULL
between	NULL
the	NULL
protein	NULL
levels	NULL
and	NULL
the	NULL
CAT	NULL
activity	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
and	NULL
evaluated	NULL
by	NULL
EMSA	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
an	NULL
aliquot	NULL
of	NULL
the	NULL
cells	NULL
.	NULL

Results	NULL
shown	NULL
represent	NULL
the	NULL
average	NULL
of	NULL
three	NULL
similar	NULL
experiments	NULL
(	NULL
differing	NULL
<	NULL
20	NULL
%	NULL
from	NULL
one	NULL
an-other	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EMSA	NULL
of	NULL
the	NULL
various	NULL
wild-type	NULL
and	NULL
mutant	NULL
Oct	NULL
proteins	NULL
observed	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
an	NULL
aliquot	NULL
of	NULL
cells	NULL
described	NULL
in	NULL
A.	NULL
Assay	NULL
and	NULL
treatment	NULL
conditions	NULL
are	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

1.	NULL
tion	NULL
over	NULL
a	NULL
range	NULL
of	NULL
0.5~5	NULL
pug	NULL
plasmid	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
A	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Likewise	NULL
,	NULL
the	NULL
antagonistic	NULL
activity	NULL
of	NULL
RA	NULL
on	NULL
Oct-2AC	NULL
was	NULL
almost	NULL
lost	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
A	NULL
)	NULL
.	NULL

Surprisingly	NULL
,	NULL
transfection	NULL
of	NULL
the	NULL
Oct-1	NULL
expression	NULL
vector	NULL
resulted	NULL
in	NULL
repression	NULL
of	NULL
the	NULL
TPA	NULL
/ionomycin-induced	NULL
activation	NULL
of	NULL
the	NULL
IL-2-OAP/OCT	NULL
1489	NULL
de	NULL
Grazia	NULL
et	NULL
al	NULL
.	NULL

tk-CAT	NULL
construct	NULL
.	NULL

Whereas	NULL
the	NULL
Oct-2	NULL
COOH	NULL
terminus	NULL
was	NULL
required	NULL
for	NULL
enhancer	NULL
transactivation	NULL
,	NULL
the	NULL
inhibitory	NULL
activity	NULL
of	NULL
Oct-1	NULL
also	NULL
mapped	NULL
to	NULL
the	NULL
COOH	NULL
terminus	NULL
,	NULL
according	NULL
to	NULL
data	NULL
recently	NULL
reported	NULL
by	NULL
Annweiler	NULL
et	NULL
al	NULL
.	NULL

(	NULL
52	NULL
)	NULL
for	NULL
the	NULL
B	NULL
cell-specific	NULL
enhancer	NULL
stimulation	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
transfection	NULL
of	NULL
Oct-1/Oct-2	NULL
chimeric	NULL
constructs	NULL
indicated	NULL
that	NULL
whenever	NULL
the	NULL
Oct-1	NULL
COOH	NULL
terminus	NULL
was	NULL
present	NULL
in	NULL
the	NULL
fusion	NULL
protein	NULL
(	NULL
Oct-2.1.1	NULL
,	NULL
Oct-1.2.1	NULL
,	NULL
Oct-2.2.1	NULL
)	NULL
,	NULL
the	NULL
transactivation	NULL
of	NULL
the	NULL
octamer	NULL
CAT	NULL
was	NULL
repressed	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Chimeric	NULL
proteins	NULL
containing	NULL
the	NULL
Oct-1	NULL
NH	NULL
;	NULL
terminus	NULL
with	NULL
Oct-2	NULL
POU	NULL
domain	NULL
and	NULL
COOH	NULL
terminus	NULL
(	NULL
Oct-1.2.2	NULL
)	NULL
or	NULL
Oct-1	NULL
POU	NULL
domain	NULL
and	NULL
Oct-2	NULL
COOH	NULL
terminus	NULL
(	NULL
Oct-1.1.2	NULL
)	NULL
(	NULL
transfected	NULL
over	NULL
a	NULL
range	NULL
of	NULL
0.5-5	NULL
ug	NULL
plasmids	NULL
)	NULL
had	NULL
comparably	NULL
lower	NULL
activity	NULL
than	NULL
Oct-2	NULL
NH	NULL
:	NULL
terminus-containing	NULL
proteins	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

They	NULL
were	NULL
,	NULL
however	NULL
,	NULL
fully	NULL
antagonized	NULL
by	NULL
RA	NULL
.	NULL

All	NULL
of	NULL
these	NULL
data	NULL
taken	NULL
together	NULL
show	NULL
that	NULL
an	NULL
intact	NULL
Oct-2	NULL
COOH-terminus	NULL
contributes	NULL
to	NULL
both	NULL
the	NULL
TPA	NULL
/ionomycin-mediated	NULL
activation	NULL
and	NULL
RA-induced	NULL
inhibition	NULL
,	NULL
suggesting	NULL
that	NULL
TPA/calcium	NULL
and	NULL
RA	NULL
signal	NULL
through	NULL
an	NULL
overlapping	NULL
pathway	NULL
.	NULL

To	NULL
investigate	NULL
this	NULL
pathway	NULL
,	NULL
we	NULL
studied	NULL
the	NULL
nuclear	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
octamer	NULL
motif	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
Composite	NULL
IL-2	NULL
Octamer	NULL
Motif	NULL
:	NULL
Presence	NULL
of	NULL
an	NULL
AP-1	NULL
Complex	NULL
and	NULL
Transcriptional	NULL
Activation	NULL
by	NULL
fos	NULL
and	NULL
jun	NULL
.	NULL

-	NULL
In	NULL
addition	NULL
to	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
,	NULL
a	NULL
TPA/calcium-inducible	NULL
nuclear	NULL
factor	NULL
,	NULL
previously	NULL
termed	NULL
OAP	NULL
``	NULL
,	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
bind	NULL
to	NULL
a	NULL
region	NULL
closely	NULL
linked	NULL
to	NULL
the	NULL
-96	NULL
to	NULL
-66-bp	NULL
IL-2	NULL
octamer-binding	NULL
site	NULL
(	NULL
29	NULL
)	NULL
.	NULL

The	NULL
OAP	NULL
binding	NULL
site	NULL
shares	NULL
five	NULL
out	NULL
of	NULL
seven	NULL
nucleotides	NULL
with	NULL
a	NULL
canonical	NULL
AP1	NULL
binding	NULL
motif	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
A	NULL
)	NULL
.	NULL

The	NULL
complex	NULL
between	NULL
the	NULL
IL-2	NULL
octamer	NULL
motif	NULL
deleted	NULL
from	NULL
the	NULL
Oct	NULL
binding	NULL
site	NULL
(	NULL
OAP/	NULL
AOCT	NULL
)	NULL
and	NULL
nuclear	NULL
factors	NULL
extracted	NULL
from	NULL
TPA	NULL
/ionomycin-activated	NULL
Jurkat	NULL
T	NULL
cells	NULL
was	NULL
displaced	NULL
by	NULL
competition	NULL
with	NULL
an	NULL
excess	NULL
of	NULL
either	NULL
unlabeled	NULL
collagenase	NULL
AP-1	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
B	NULL
,	NULL
AP1	NULL
Coll	NULL
)	NULL
or	NULL
the	NULL
proximal	NULL
(	NULL
~160	NULL
to	NULL
-139-bp	NULL
)	NULL
AP-1	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
which	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
jun	NULL
and	NULL
fos	NULL
proteins	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
21	NULL
,	NULL
53	NULL
)	NULL
.	NULL

An	NULL
unlabeled	NULL
OAP/AOCT	NULL
also	NULL
competed	NULL
for	NULL
proteins	NULL
from	NULL
activated	NULL
T	NULL
cells	NULL
that	NULL
bind	NULL
to	NULL
an	NULL
AP-1	NULL
site	NULL
from	NULL
the	NULL
collagenase	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
B	NULL
,	NULL
OAP	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
observed	NULL
with	NULL
HeLa	NULL
cell	NULL
nuclear	NULL
extracts	NULL
as	NULL
a	NULL
source	NULL
of	NULL
AP-1	NULL
factor	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
B	NULL
)	NULL
.	NULL

We	NULL
also	NULL
observed	NULL
that	NULL
antibodies	NULL
against	NULL
both	NULL
fos	NULL
and	NULL
jun	NULL
proteins	NULL
were	NULL
able	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
complex	NULL
formed	NULL
by	NULL
nuclear	NULL
factors	NULL
(	NULL
from	NULL
both	NULL
Jurkat	NULL
and	NULL
Hela	NULL
cells	NULL
)	NULL
and	NULL
the	NULL
OAP/AOCT	NULL
sequence	NULL
motif	NULL
,	NULL
whereas	NULL
an	NULL
unrelated	NULL
antibody	NULL
was	NULL
uneffec-tive	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
C	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
result	NULL
suggests	NULL
that	NULL
the	NULL
protein	NULL
complex	NULL
that	NULL
binds	NULL
to	NULL
the	NULL
OAP/AOCT	NULL
sequence	NULL
contains	NULL
fos	NULL
and	NULL
jun	NULL
family	NULL
members	NULL
,	NULL
which	NULL
are	NULL
components	NULL
of	NULL
AP-1	NULL
.	NULL

The	NULL
OAP/AOCT	NULL
sequence	NULL
not	NULL
only	NULL
binds	NULL
an	NULL
AP-1	NULL
factor	NULL
,	NULL
but	NULL
its	NULL
cis-regulatory	NULL
function	NULL
is	NULL
also	NULL
activated	NULL
by	NULL
jun	NULL
and	NULL
fos	NULL
.	NULL

Fig	NULL
.	NULL

4	NULL
shows	NULL
that	NULL
cotransfection	NULL
of	NULL
vectors	NULL
encoding	NULL
either	NULL
c-jun	NULL
,	NULL
jun-B	NULL
,	NULL
or	NULL
jun-D	NULL
with	NULL
pCG-Oct-2	NULL
(	NULL
Oct2	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
TPA/ionomycin	NULL
treatment	NULL
could	NULL
partially	NULL
substitute	NULL
for	NULL
PKC	NULL
and	NULL
calcium-mediated	NULL
signals	NULL
in	NULL
the	NULL
transactivation	NULL
of	NULL
the	NULL
IL-2-OAP/OCT-tk-CAT	NULL
reporter	NULL
.	NULL

Similar	NULL
transactivation	NULL
was	NULL
observed	NULL
by	NULL
cotransfecting	NULL
Oct-2	NULL
with	NULL
c-fos	NULL
or	NULL
Fos-B	NULL
,	NULL
which	NULL
are	NULL
likely	NULL
to	NULL
form	NULL
heterodimer	NULL
complexes	NULL
with	NULL
the	NULL
endogenous	NULL
jun-D	NULL
,	NULL
which	NULL
has	NULL
been	NULL
recently	NULL
reported	NULL
-	NULL
nuclear	NULL
extract	NULL
A	NULL
B	NULL
$	NULL
0	NULL
+	NULL
8	NULL
o	NULL
$	NULL
cos	NULL
40	NULL
>	NULL
o	NULL
>	NULL
4	NULL
4	NULL
+	NULL
o	NULL
>	NULL
Hela	NULL
C	NULL
+	NULL
4	NULL
+	NULL
+	NULL
+	NULL
+0	NULL
+	NULL
+/+	NULL
+	NULL
0+	NULL
-	NULL
4	NULL
4	NULL
Jurkat	NULL
£0	NULL
.	NULL

$	NULL
+	NULL
+	NULL
>	NULL
4	NULL
-	NULL
+	NULL
a-Fos	NULL
TPA	NULL
+	NULL
lon	NULL
-	NULL
-	NULL
+	NULL
+	NULL
sop	NULL
+	NULL
g	NULL
4	NULL
+	NULL
c	NULL
4	NULL
+	NULL
+	NULL
4	NULL
4	NULL
Tpaslon	NULL
-o	NULL
¥	NULL
>	NULL
o	NULL
>	NULL
>	NULL
4	NULL
>	NULL
a-Jun	NULL
+	NULL
M	NULL
-	NULL
f	NULL
8	NULL
8	NULL
+o+	NULL
+	NULL
4	NULL
AP1	NULL
Coll	NULL
sot	NULL
t	NULL
ot	NULL
#	NULL
toto	NULL
>	NULL
o	NULL
&	NULL
a-B	NULL
gal	NULL
competitor	NULL
-	NULL
3	NULL
,	NULL
3	NULL
-o	NULL
4	NULL
>	NULL
>	NULL
o	NULL
>	NULL
4	NULL
-	NULL
4	NULL
>	NULL
OAP	NULL
+	NULL
0+	NULL
+	NULL
+	NULL
.	NULL

TPA+lon	NULL
2	NULL
,	NULL
<	NULL
OAP/Oct1	NULL
bt	NULL
u	NULL
<	NULL
O0ct1	NULL
4	NULL
>	NULL
H	NULL
H	NULL
.	NULL

+80	NULL
.69	NULL
.56	NULL
#	NULL
604	NULL
}	NULL
l	NULL
OAP	NULL
Oct	NULL
OAP	NULL
:	NULL
T	NULL
GT	NULL
G	NULL
T	NULL
A	NULL
A	NULL
14	NULL
d	NULL
bd	NULL
AP1	NULL
Coll	NULL
:	NULL
T	NULL
G	NULL
A	NULL
G	NULL
T	NULL
C	NULL
A	NULL
L	NULL
JL	NULL
I	NULL
L_	NULL
oar	NULL
:	NULL
AoctT	NULL
AP1	NULL
Coll	NULL
probes	NULL
Figure	NULL
3	NULL
.	NULL

Detection	NULL
of	NULL
jun/fos/AP-1	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
IL-2	NULL
octamer	NULL
motif	NULL
in	NULL
Jurkat	NULL
cell	NULL
nuclear	NULL
extracts	NULL
.	NULL

(	NULL
4	NULL
)	NULL
EMSA	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
treated	NULL
with	NULL
or	NULL
without	NULL
TPA	NULL
and	NULL
ionomycin	NULL
,	NULL
binding	NULL
to	NULL
the	NULL
OAP/OCT	NULL
oligonucleotide	NULL
represented	NULL
on	NULL
the	NULL
bottom	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
a	NULL
50-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
OAP/OCT	NULL
competitor	NULL
oligonucleotide	NULL
.	NULL

Arrowheads	NULL
indicate	NULL
the	NULL
Oct-1	NULL
complex	NULL
alone	NULL
or	NULL
the	NULL
combined	NULL
OAP/Oct-1	NULL
supershifted	NULL
complex	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EMSA	NULL
of	NULL
unstimulated	NULL
Jurkat	NULL
and	NULL
Hela	NULL
cell	NULL
and	NULL
4-h	NULL
TPA/calcium-stimulated	NULL
Jurkat	NULL
cell	NULL
nuclear	NULL
extracts	NULL
binding	NULL
to	NULL
either	NULL
the	NULL
OAP	NULL
site	NULL
deleted	NULL
of	NULL
octamer	NULL
sequences	NULL
(	NULL
OAP/AOCT	NULL
,	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
or	NULL
the	NULL
AP-1	NULL
consensus	NULL
sequence	NULL
from	NULL
the	NULL
collagenase	NULL
promoter	NULL
(	NULL
AP-1coll	NULL
,	NULL
5-GATCCGGCTGACTCATCA-3	NULL
'	NULL
)	NULL
.	NULL

A	NULL
50-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
OAP	NULL
or	NULL
AP-1coll	NULL
(	NULL
B	NULL
)	NULL
competitor	NULL
oligonucleotides	NULL
were	NULL
included	NULL
in	NULL
the	NULL
binding	NULL
reaction	NULL
as	NULL
indicated	NULL
above	NULL
each	NULL
lane	NULL
.	NULL

Arrowheads	NULL
indicate	NULL
the	NULL
specific	NULL
TPA/Ca	NULL
?	NULL

*-inducible	NULL
AP-1	NULL
complex	NULL
.	NULL

(	NULL
C	NULL
)	NULL
EMSA	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
either	NULL
untreated	NULL
or	NULL
TPA	NULL
/ionomycin-treated	NULL
(	NULL
for	NULL
4	NULL
h	NULL
)	NULL
Jurkat	NULL
cells	NULL
incubated	NULL
with	NULL
labeled	NULL
OAP/AOCT	NULL
probe	NULL
for	NULL
30	NULL
min	NULL
and	NULL
then	NULL
further	NULL
incubated	NULL
with	NULL
antibodies	NULL
against	NULL
either	NULL
fos	NULL
(	NULL
-Fos	NULL
)	NULL
,	NULL
jun	NULL
(	NULL
c-jun	NULL
)	NULL
or	NULL
-galactosidase	NULL
(	NULL
-	NULL
gal	NULL
)	NULL
proteins	NULL
.	NULL

Fos	NULL
and	NULL
jun	NULL
antibodies	NULL
recognize	NULL
all	NULL
members	NULL
of	NULL
the	NULL
fos	NULL
and	NULL
jun	NULL
families	NULL
,	NULL
respectively	NULL
.	NULL

Arrowheads	NULL
indicate	NULL
either	NULL
the	NULL
specific	NULL
AP-1	NULL
complex	NULL
or	NULL
a	NULL
complete	NULL
or	NULL
partial	NULL
supershift	NULL
of	NULL
the	NULL
TPA/ionomycin-inducible	NULL
complex	NULL
by	NULL
x-fos	NULL
and	NULL
x-fun	NULL
,	NULL
respectively	NULL
.	NULL

Additional	NULL
complexes	NULL
moving	NULL
faster	NULL
than	NULL
OAP	NULL
band	NULL
(	NULL
shown	NULL
in	NULL
B	NULL
and	NULL
C	NULL
)	NULL
represent	NULL
nonspecific	NULL
complexes	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
competition	NULL
using	NULL
several	NULL
competitor	NULL
oligonucleotides	NULL
(	NULL
including	NULL
nonspecific	NULL
and	NULL
self-competitors	NULL
)	NULL
as	NULL
well	NULL
as	NULL
different	NULL
amounts	NULL
of	NULL
Poly	NULL
(	NULL
dl-dC	NULL
)	NULL
.	NULL

to	NULL
be	NULL
constitutively	NULL
expressed	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
54	NULL
)	NULL
.	NULL

No	NULL
significant	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
was	NULL
observed	NULL
when	NULL
jun	NULL
and	NULL
fos	NULL
expression	NULL
vectors	NULL
were	NULL
transfected	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
Oct-2	NULL
vector	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
pCG	NULL
)	NULL
.	NULL

The	NULL
OAP	NULL
cis-Element	NULL
Synergizes	NULL
with	NULL
the	NULL
Oct-2	NULL
Octamer	NULL
Complex	NULL
and	NULL
is	NULL
Negatively	NULL
Regulated	NULL
by	NULL
RAR	NULL
.	NULL

-	NULL
The	NULL
ability	NULL
of	NULL
fos	NULL
and	NULL
jun	NULL
to	NULL
synergize	NULL
with	NULL
Oct-2	NULL
in	NULL
enhancing	NULL
the	NULL
IL-2	NULL
octamer	NULL
motif	NULL
suggests	NULL
that	NULL
both	NULL
elements	NULL
may	NULL
be	NULL
required	NULL
to	NULL
drive	NULL
transcription	NULL
.	NULL

To	NULL
address	NULL
this	NULL
point	NULL
,	NULL
we	NULL
introduced	NULL
mutations	NULL
or	NULL
deletions	NULL
in	NULL
either	NULL
or	NULL
both	NULL
OAP-	NULL
and	NULL
OCT	NULL
-binding	NULL
sites	NULL
and	NULL
tested	NULL
their	NULL
cis-regulatory	NULL
activity	NULL
on	NULL
a	NULL
heterologous	NULL
tk	NULL
promoter	NULL
.	NULL

We	NULL
first	NULL
studied	NULL
the	NULL
binding	NULL
specificity	NULL
of	NULL
these	NULL
sequences	NULL
versus	NULL
OAP	NULL
,	NULL
Oct-1	NULL
,	NULL
and	NULL
Oct-2	NULL
proteins	NULL
by	NULL
testing	NULL
their	NULL
ability	NULL
to	NULL
compete	NULL
for	NULL
binding	NULL
to	NULL
radiolabeled	NULL
OAP/OCT	NULL
or	NULL
OAP/AOCT	NULL
probes	NULL
.	NULL

Oligonucleotides	NULL
carrying	NULL
substitution	NULL
mutations	NULL
or	NULL
a	NULL
deletion	NULL
of	NULL
the	NULL
OAP	NULL
binding	NULL
site	NULL
(	NULL
mOAP/OCT	NULL
and	NULL
AOAP/OCT	NULL
,	NULL
respectively	NULL
)	NULL
competed	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
wild-type	NULL
OAP/OCT	NULL
motif	NULL
for	NULL
in	NULL
vitro	NULL
translated	NULL
Oct-2	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
A	NULL
,	NULL
lanes	NULL
4-6	NULL
)	NULL
or	NULL
endogenous	NULL
Oct-1	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
B	NULL
,	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
and	NULL
5	NULL
)	NULL
,	NULL
but	NULL
they	NULL
did	NULL
not	NULL
bind	NULL
the	NULL
OAP	NULL
factors	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
B	NULL
,	NULL
lanes	NULL
4	NULL
,	NULL
5	NULL
,	NULL
14	NULL
,	NULL
and	NULL
15	NULL
)	NULL
.	NULL

Mutations	NULL
or	NULL
deletions	NULL
of	NULL
the	NULL
octamer-binding	NULL
sequence	NULL
(	NULL
OAP/mOCT	NULL
and	NULL
OAP/AOCT	NULL
,	NULL
respectively	NULL
)	NULL
abolished	NULL
the	NULL
DNA-binding	NULL
ability	NULL
of	NULL
Oct-2	NULL
and	NULL
Oct-1	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
A	NULL
,	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
and	NULL
Fig	NULL
.	NULL

5	NULL
B	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
but	NULL
1490	NULL
they	NULL
still	NULL
allowed	NULL
binding	NULL
of	NULL
the	NULL
OAP	NULL
factors	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
B	NULL
,	NULL
lanes	NULL
3	NULL
,	NULL
12	NULL
,	NULL
and	NULL
13	NULL
)	NULL
.	NULL

An	NULL
analysis	NULL
of	NULL
the	NULL
functional	NULL
activity	NULL
of	NULL
the	NULL
mutated	NULL
cis-regulatory	NULL
motifs	NULL
indicated	NULL
that	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
double-mutated	NULL
OAP/OCT	NULL
element	NULL
(	NULL
m	NULL
(	NULL
OAP/OCT	NULL
)	NULL
-tk-CAT	NULL
)	NULL
,	NULL
OAP/mOCT	NULL
(	NULL
OAP/mOCT-tk-CAT	NULL
)	NULL
,	NULL
or	NULL
OAP/	NULL
AOCT	NULL
(	NULL
OAP/AOCT-tk-CAT	NULL
)	NULL
driving	NULL
CAT	NULL
expression	NULL
through	NULL
a	NULL
tk	NULL
promoter	NULL
were	NULL
unable	NULL
to	NULL
be	NULL
transactivated	NULL
by	NULL
Oct-2	NULL
in	NULL
response	NULL
to	NULL
TPA	NULL
and	NULL
ionomycin	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

This	NULL
result	NULL
suggests	NULL
that	NULL
the	NULL
AP-1-binding	NULL
OAP	NULL
element	NULL
has	NULL
weak	NULL
enhancer	NULL
activity	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
concomitant	NULL
Oct-2	NULL
binding	NULL
.	NULL

The	NULL
abrogation	NULL
of	NULL
OAP	NULL
binding	NULL
(	NULL
mOAP/OCT	NULL
-tk-CAT	NULL
and	NULL
AOAP/OCT-tk-CAT	NULL
)	NULL
also	NULL
impaired	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
octamer	NULL
motif	NULL
to	NULL
be	NULL
transactivated	NULL
by	NULL
Oct-2	NULL
in	NULL
response	NULL
to	NULL
TPA	NULL
and	NULL
ionomycin	NULL
by	NULL
~90	NULL
%	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
B	NULL
)	NULL
.	NULL

This	NULL
result	NULL
suggests	NULL
that	NULL
Oct-2	NULL
has	NULL
very	NULL
weak	NULL
enhancer	NULL
activity	NULL
in	NULL
response	NULL
to	NULL
TPA	NULL
and	NULL
ionomycin	NULL
without	NULL
concomitant	NULL
AP-1	NULL
binding	NULL
.	NULL

Thus	NULL
,	NULL
both	NULL
cis-elements	NULL
appear	NULL
to	NULL
require	NULL
mutual	NULL
cooperation	NULL
for	NULL
full	NULL
enhancer	NULL
properties	NULL
.	NULL

Of	NULL
further	NULL
interest	NULL
is	NULL
the	NULL
observation	NULL
that	NULL
mutation	NULL
or	NULL
deletion	NULL
of	NULL
the	NULL
OAP	NULL
binding	NULL
motif	NULL
almost	NULL
completely	NULL
abrogated	NULL
the	NULL
ability	NULL
to	NULL
RA	NULL
to	NULL
antagonize	NULL
the	NULL
TPA/ionomycin-induced	NULL
Oct-2-dependent	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
octamer	NULL
binding	NULL
site	NULL
;	NULL
this	NULL
is	NULL
probably	NULL
due	NULL
to	NULL
the	NULL
very	NULL
low	NULL
TPA	NULL
/ionomycin-induced	NULL
activation	NULL
ob-served	NULL
.	NULL

Thus	NULL
,	NULL
RA	NULL
inhibition	NULL
was	NULL
observed	NULL
only	NULL
when	NULL
both	NULL
IL-2	NULL
Octamer	NULL
Regulation	NULL
by	NULL
Ap-1	NULL
,	NULL
Oct-2	NULL
,	NULL
and	NULL
RAR	NULL
TPA+lon	NULL
vector	NULL
vector	NULL
c-jun	NULL
jun-B	NULL
,	NULL
Figure	NULL
4	NULL
.	NULL

|	NULL
Transactivation	NULL
of	NULL
the	NULL
II-2-OAP/OCT	NULL
cis-element	NULL
by	NULL
jun	NULL
or	NULL
jun-D	NULL
fos	NULL
and	NULL
Oct-2	NULL
expression	NULL
vectors	NULL
in	NULL
unactivated	NULL
Jurkat	NULL
cells	NULL
.	NULL

Empty	NULL
vectors	NULL
(	NULL
pRAXneo	NULL
,	NULL
pUC-RSV	NULL
,	NULL
or	NULL
pCMV-1	NULL
)	NULL
,	NULL
c-jun	NULL
,	NULL
jun-B	NULL
,	NULL
jun-D	NULL
,	NULL
c-fos	NULL
,	NULL
or	NULL
Fos-B	NULL
expression	NULL
vectors	NULL
were	NULL
cotransfected	NULL
together	NULL
with	NULL
IL-2-OAP/OCT-tk-c-fos	NULL
CAT	NULL
and	NULL
either	NULL
pCG-Oct2	NULL
or	NULL
pCG	NULL
plasmids	NULL
into	NULL
Jurkat	NULL
cells	NULL
.	NULL

Where	NULL
in-dicated	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
24	NULL
h	NULL
later	NULL
with	NULL
TPA	NULL
and	NULL
ionomycin	NULL
(	NULL
TPA	NULL
+	NULL
FosB	NULL
Tony	NULL
.	NULL

CAT	NULL
assays	NULL
in	NULL
cell	NULL
extracts	NULL
were	NULL
carried	NULL
out	NULL
48	NULL
h	NULL
after	NULL
transfection	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
average	NULL
(	NULL
+SE	NULL
from	NULL
three	NULL
experiments	NULL
)	NULL
fold	NULL
0	NULL
10	NULL
increase	NULL
of	NULL
the	NULL
CAT	NULL
activity	NULL
observed	NULL
compared	NULL
with	NULL
untreated	NULL
empty	NULL
IL2-O0AP/OCT-tk-CAT	NULL
vector-transfected	NULL
cells	NULL
(	NULL
basal	NULL
activity	NULL
125	NULL
+	NULL
20	NULL
and	NULL
180	NULL
+	NULL
30	NULL
pmol/h/mg	NULL
(	NULL
fold	NULL
increase	NULL
versus	NULL
empty	NULL
vector	NULL
)	NULL
protein	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
and	NULL
presence	NULL
of	NULL
Oct-2	NULL
,	NULL
respectively	NULL
}	NULL
.	NULL

A	NULL
-	NULL
RRL	NULL
+	NULL
Oct2	NULL
B	NULL
§	NULL
>	NULL
E	NULL
§	NULL
a	NULL
o	NULL
=	NULL
tope	NULL
b-	NULL
<	NULL
<	NULL
Roj	NULL
b	NULL
£	NULL
m	NULL
!	NULL

s	NULL
.Lo	NULL
o	NULL
o	NULL
80	NULL
t	NULL
iG	NULL
bo	NULL
6	NULL
o	NULL
9	NULL
80	NULL
E20	NULL
556559	NULL
ebo	NULL
o	NULL
o	NULL
2	NULL
5	NULL
ff	NULL
809000	NULL
9	NULL
E	NULL
o	NULL
o	NULL
9	NULL
o	NULL
0	NULL
5	NULL
o	NULL
o	NULL
E	NULL
a	NULL
a	NULL
%	NULL
9	NULL
o	NULL
o	NULL
-	NULL
E	NULL
a	NULL
a	NULL
t	NULL
a	NULL
go	NULL
-	NULL
&	NULL
%	NULL
E	NULL
c	NULL
<	NULL
*	NULL
%	NULL
&	NULL
6	NULL
o	NULL
°	NULL
#	NULL
s	NULL
0	NULL
00	NULL
&	NULL
&	NULL
6	NULL
o	NULL
9	NULL
s	NULL
#	NULL
os	NULL
\	NULL
a	NULL
O	NULL
§	NULL
£19	NULL
s	NULL
so	NULL
-	NULL
EoE	NULL
Ek	NULL
gg	NULL
2	NULL
3	NULL
8	NULL
-	NULL
rr	NULL
&	NULL
a=	NULL
c	NULL
O	NULL
E	NULL
<	NULL
o	NULL
o	NULL
E	NULL
+	NULL
t	NULL
4	NULL
t+	NULL
%	NULL
4+	NULL
-o-	NULL
-	NULL
+	NULL
4	NULL
4	NULL
+	NULL
+	NULL
+	NULL
+	NULL
TPAslon	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10112134	NULL
66	NULL
OAP/Oct1	NULL
®	NULL
»	NULL
h	NULL
@	NULL
J	NULL
Oct2	NULL
»	NULL
@	NULL
©	NULL
o	NULL
0	NULL
bo	NULL
44	NULL
iQ	NULL
M	NULL
}	NULL
#	NULL
<	NULL
oar	NULL
.cobdih	NULL
din	NULL
n.	NULL
AM	NULL
OoAP/0CT	NULL
probes	NULL
Hum	NULL
bm	NULL
..	NULL
II	NULL
I	NULL
*	NULL
t	NULL
RHMMEh	NULL
as	NULL
ha	NULL
ba	NULL
]	NULL
QAP/OCT	NULL
OAP	NULL
1	NULL
OCT	NULL
Figure	NULL
5	NULL
.	NULL

-	NULL
Binding	NULL
specificity	NULL
of	NULL
OAP/OCT	NULL
motif	NULL
through	NULL
competition	NULL
assays	NULL
using	NULL
oligonucleotides	NULL
carrying	NULL
mutations	NULL
or	NULL
deletions	NULL
in	NULL
the	NULL
OAP	NULL
{	NULL
mOAP/OCT	NULL
and	NULL
AOAP/OCT	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
octamer	NULL
(	NULL
QAP/mOCT	NULL
and	NULL
OAP/AOCT	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
or	NULL
both	NULL
sites	NULL
[	NULL
m	NULL
{	NULL
OAP/OCT	NULL
)	NULL
]	NULL
.	NULL

Mutated	NULL
oligonucleotides	NULL
are	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

(	NULL
A	NULL
)	NULL
EMSA	NULL
of	NULL
in	NULL
vitro	NULL
synthesized	NULL
Oct-2	NULL
protein	NULL
(	NULL
RRL	NULL
+	NULL
Oct2	NULL
,	NULL
arrowhead	NULL
)	NULL
or	NULL
unprogrammed	NULL
RRL	NULL
binding	NULL
to	NULL
labeled	NULL
OAP/OCT	NULL
probe	NULL
.	NULL

The	NULL
50-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
competitor	NULL
oligonucleotides	NULL
are	NULL
indicated	NULL
above	NULL
each	NULL
lane	NULL
.	NULL

Arrowhead	NULL
indicates	NULL
the	NULL
Oct-2	NULL
protein-DNA	NULL
complex	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EMSA	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
stimulated	NULL
with	NULL
TPA	NULL
and	NULL
ionomycin	NULL
for	NULL
4	NULL
h	NULL
,	NULL
binding	NULL
to	NULL
either	NULL
OAP/OCT	NULL
or	NULL
the	NULL
OAP	NULL
sequence	NULL
alone	NULL
(	NULL
OAP/AOCT	NULL
)	NULL
as	NULL
probes	NULL
.	NULL

For	NULL
the	NULL
competition	NULL
assays	NULL
,	NULL
a	NULL
50-fold	NULL
excess	NULL
of	NULL
the	NULL
unlabeled	NULL
oligonucleotides	NULL
indicated	NULL
above	NULL
each	NULL
lane	NULL
(	NULL
including	NULL
a	NULL
nonspecific	NULL
sequence	NULL
(	NULL
NS	NULL
)	NULL
]	NULL
were	NULL
used	NULL
.	NULL

RRL	NULL
and	NULL
RRL+	NULL
Oct1	NULL
indicate	NULL
the	NULL
complex	NULL
formed	NULL
by	NULL
in	NULL
vitro	NULL
synthesized	NULL
Oct-1	NULL
protein	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Arrowheads	NULL
indicate	NULL
the	NULL
Oct-1	NULL
or	NULL
OAP	NULL
complexes	NULL
alone	NULL
or	NULL
the	NULL
combined	NULL
OAP/Oct-1	NULL
supershifted	NULL
complex	NULL
.	NULL

1491	NULL
de	NULL
Grazia	NULL
et	NULL
al	NULL
.	NULL

OAP	NULL
Octamer	NULL
TTGAAAATATGIGTAA	NULL
T	NULL
ATGTAAAACATTT	NULL
IL2-m	NULL
(	NULL
OAP/OCT	NULL
)	NULL
:	NULL
TTGAAAATATGTGTec	NULL
T	NULL
cgagg	NULL
ACAT	NULL
!	NULL

T	NULL
ATGTAAAACATTT	NULL
T	NULL
ATGTAAAACATTT	NULL
TTGAAAATATGTIGTAA	NULL
T	NULL
ATT	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
-TTGAAAATATGTGIAA	NULL
T	NULL
ATaatActCA	NULL
TT	NULL
!	NULL

IL2-OAP/OCT	NULL
:	NULL
IL2-AOAP/OCT	NULL
:	NULL
IL2-mOAP/OCT	NULL
:	NULL
IL2-OAP/AOCT	NULL
:	NULL
IL2-OAP/mOCT	NULL
:	NULL
B	NULL
IL2-OAPIOCT	NULL
tk	NULL
CAT	NULL
m	NULL
{	NULL
lL2-0AP/OCT	NULL
)	NULL
tk	NULL
CAT	NULL
IL2-AOAP/OCT	NULL
tk	NULL
CAT	NULL
[	NULL
CJ	NULL
Basal	NULL
TPA	NULL
+	NULL
ion	NULL
IL2-mOAP/OCT	NULL
tk	NULL
CAT	NULL
B	NULL
TPA+ion+	NULL
RA	NULL
IL2-OAPMOCT	NULL
tk	NULL
CAT	NULL
IL2-0AP/mOCT	NULL
tk	NULL
CAT	NULL
AP1coll	NULL
tk	NULL
CAT	NULL
o	NULL
10	NULL
20	NULL
so	NULL
40	NULL
so	NULL
CAT	NULL
ACTIVITY	NULL
(	NULL
fold	NULL
induction	NULL
versus	NULL
basal	NULL
)	NULL
OAP-	NULL
and	NULL
Oct-2-binding	NULL
sites	NULL
were	NULL
allowed	NULL
to	NULL
synergize	NULL
with	NULL
each	NULL
other	NULL
.	NULL

RAR	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
antagonize	NULL
the	NULL
collagenase	NULL
AP-1	NULL
enhancer	NULL
activity	NULL
in	NULL
Hela	NULL
cells	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
a	NULL
similar	NULL
RAR-AP-1	NULL
antagonism	NULL
might	NULL
occur	NULL
at	NULL
the	NULL
IL-2-OAP	NULL
motif	NULL
in	NULL
T	NULL
cells	NULL
We	NULL
therefore	NULL
studied	NULL
the	NULL
effect	NULL
of	NULL
RA	NULL
on	NULL
the	NULL
TPA/ionomycin-induced	NULL
activation	NULL
of	NULL
five	NULL
copies	NULL
of	NULL
the	NULL
collagenase	NULL
AP-1	NULL
cis-element	NULL
driving	NULL
CAT	NULL
transcription	NULL
through	NULL
Figure	NULL
6	NULL
.	NULL

-	NULL
Functional	NULL
analysis	NULL
of	NULL
Oct-2	NULL
transactivating	NULL
activity	NULL
in	NULL
responsive	NULL
sequences	NULL
mutated	NULL
either	NULL
in	NULL
the	NULL
OAP	NULL
(	NULL
IL	NULL
22A0AP/OCTtk-CAT	NULL
,	NULL
IL	NULL
;	NULL
2-m0AP/OCT	NULL
-CAT	NULL
)	NULL
,	NULL
octamer	NULL
(	NULL
IL2-:04P/AOCTtk-CAT	NULL
,	NULL
IL2-:04P/	NULL
mOCTik-CAT	NULL
)	NULL
,	NULL
or	NULL
both	NULL
sites	NULL
(	NULL
m	NULL
[	NULL
IL2-OAP/OCT	NULL
}	NULL
tk-CAT	NULL
)	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Description	NULL
of	NULL
the	NULL
mutated	NULL
oligonucleotides	NULL
cloned	NULL
as	NULL
four-copy	NULL
concatemers	NULL
in	NULL
front	NULL
of	NULL
the	NULL
(	NULL
-105	NULL
)	NULL
-tk-CAT	NULL
fusion	NULL
reporter	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Each	NULL
reporter	NULL
plasmid	NULL
shown	NULL
in	NULL
A	NULL
or	NULL
AP1coll-tk-CAT	NULL
(	NULL
4	NULL
ug	NULL
)	NULL
was	NULL
cotransfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
together	NULL
with	NULL
pCG-Oct-2	NULL
and	NULL
RARa	NULL
«	NULL
(	NULL
ug	NULL
)	NULL
expression	NULL
vectors	NULL
.	NULL

After	NULL
24	NULL
h	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
TPA	NULL
and	NULL
ionomycin	NULL
or	NULL
RA	NULL
as	NULL
indicated	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
further	NULL
processed	NULL
for	NULL
CAT	NULL
assay	NULL
24	NULL
h	NULL
later	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
average	NULL
(	NULL
+SE	NULL
from	NULL
three	NULL
experiments	NULL
)	NULL
fold	NULL
increase	NULL
of	NULL
the	NULL
CAT	NULL
activity	NULL
observed	NULL
in	NULL
drug-treated	NULL
relative	NULL
to	NULL
untreated	NULL
(	NULL
basal	NULL
)	NULL
cells	NULL
after	NULL
subtraction	NULL
of	NULL
the	NULL
CAT	NULL
activity	NULL
expressed	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
transfected	NULL
Oct-2	NULL
.	NULL

Basal	NULL
CAT	NULL
activity	NULL
values	NULL
(	NULL
pmol/h/mg	NULL
protein	NULL
)	NULL
were	NULL
160	NULL
+	NULL
25	NULL
(	NULL
IL20AP/OCT	NULL
tk-CAT	NULL
)	NULL
;	NULL
100	NULL
+	NULL
20	NULL
(	NULL
m	NULL
[	NULL
IL20A4P/OCTJkCAT	NULL
)	NULL
;	NULL
138	NULL
+	NULL
15	NULL
(	NULL
IL2	NULL
AOAP/OCTikCAT	NULL
)	NULL
,	NULL
127	NULL
+	NULL
6	NULL
(	NULL
IL2mOAP/OCTitkECAT	NULL
)	NULL
,	NULL
94	NULL
+	NULL
8	NULL
(	NULL
IL	NULL
2-0AP/AOCTik-CAT	NULL
)	NULL
,	NULL
80	NULL
+	NULL
15	NULL
(	NULL
IL2-.04P/mOCTik-CAT	NULL
)	NULL
,	NULL
and	NULL
52	NULL
+	NULL
5	NULL
(	NULL
APlcoll-tk-CAT	NULL
)	NULL
.	NULL

the	NULL
tk	NULL
promoter	NULL
.	NULL

Fig	NULL
.	NULL

6	NULL
B	NULL
shows	NULL
that	NULL
RA	NULL
treatment	NULL
resulted	NULL
in	NULL
a	NULL
decrease	NULL
of	NULL
the	NULL
TPA/ionomycin-induced	NULL
activation	NULL
of	NULL
AP-1-coll-tk-CAT	NULL
cotransfected	NULL
with	NULL
an	NULL
RAR	NULL
expression	NULL
vector	NULL
into	NULL
Jurkat	NULL
cells	NULL
.	NULL

RARao	NULL
Inhibits	NULL
OAP	NULL
Binding	NULL
Activity	NULL
in	NULL
Vitro	NULL
To	NULL
study	NULL
the	NULL
RAR	NULL
domains	NULL
involved	NULL
in	NULL
the	NULL
antagonism	NULL
of	NULL
the	NULL
TPA	NULL
/ionomycin-induced	NULL
activation	NULL
of	NULL
OAP/OCT	NULL
cis-elements	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
effects	NULL
of	NULL
RARo	NULL
mutant	NULL
expression	NULL
vectors	NULL
Figure	NULL
7	NULL
.	NULL

-	NULL
The	NULL
RARa	NULL
DNA-binding	NULL
domain	NULL
is	NULL
necessary	NULL
for	NULL
the	NULL
RA-mediated	NULL
repression	NULL
of	NULL
the	NULL
11I	NULL
>	NULL
2	NULL
octamer	NULL
motif	NULL
.	NULL

Wild-type	NULL
and	NULL
deletion	NULL
mutants	NULL
(	NULL
1	NULL
ug	NULL
)	NULL
of	NULL
RARa	NULL
«	NULL
receptor	NULL
were	NULL
cotransfected	NULL
either	NULL
with	NULL
IL-2-OAP/OCT-tk-CAT	NULL
(	NULL
4	NULL
Lg	NULL
)	NULL
or	NULL
TREp2-CAT	NULL
(	NULL
4	NULL
ug	NULL
)	NULL
in	NULL
an	NULL
RA-resistant	NULL
Jurkat	NULL
cell	NULL
subclone	NULL
.	NULL

On	NULL
the	NULL
left	NULL
,	NULL
the	NULL
wild-type	NULL
(	NULL
RARa	NULL
)	NULL
,	NULL
amino	NULL
(	NULL
A1-81	NULL
)	NULL
,	NULL
and	NULL
DNA-binding	NULL
(	NULL
A81-153	NULL
)	NULL
deleted	NULL
receptors	NULL
are	NULL
schematically	NULL
illus-trated	NULL
.	NULL

Numbers	NULL
over	NULL
the	NULL
various	NULL
FA	NULL
-RA	NULL
moran	NULL
Ce	NULL
?	NULL

``	NULL
T	NULL
1	NULL
We	NULL
?	NULL

”	NULL
rrr	NULL
-C	NULL
)	NULL
Roo	NULL
TPA/lon-induced	NULL
IL2-0AP/OCT-CAT	NULL
activity	NULL
T	NULL
T	NULL
t	NULL
10	NULL
20	NULL
30	NULL
TREp2CAT	NULL
activity	NULL
receptors	NULL
indicate	NULL
amino	NULL
acid	NULL
po-sitions	NULL
,	NULL
and	NULL
the	NULL
filled	NULL
box	NULL
represents	NULL
the	NULL
DNA-binding	NULL
do	NULL
main	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
treated	NULL
and	NULL
processed	NULL
for	NULL
CAT	NULL
assay	NULL
as	NULL
previously	NULL
described	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
CAT	NULL
activity	NULL
relative	NULL
to	NULL
the	NULL
100	NULL
%	NULL
TPA/ionomycin-induced	NULL
activation	NULL
of	NULL
IL-2-OAP/OCT-tk-CAT	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
RA	NULL
treatment	NULL
.	NULL

Similar	NULL
levels	NULL
of	NULL
TPA/ionomycin-induced	NULL
IL-	NULL
2-OAP/OCT-tk-CAT	NULL
activity	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
RA	NULL
treatment	NULL
were	NULL
observed	NULL
in	NULL
untransfected	NULL
cells	NULL
and	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
various	NULL
RAR	NULL
expression	NULL
vectors	NULL
.	NULL

For	NULL
TREp2-CAT	NULL
,	NULL
results	NULL
are	NULL
expressed	NULL
as	NULL
RA-induced	NULL
fold	NULL
activation	NULL
of	NULL
CAT	NULL
activity	NULL
relative	NULL
to	NULL
RA-untreated	NULL
cells	NULL
.	NULL

The	NULL
various	NULL
RAR	NULL
expression	NULL
vectors	NULL
did	NULL
not	NULL
influence	NULL
the	NULL
TREp2-CAT	NULL
activity	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
RA	NULL
treatment	NULL
.	NULL

Results	NULL
shown	NULL
represent	NULL
the	NULL
average	NULL
(	NULL
+SE	NULL
)	NULL
of	NULL
three	NULL
experiments	NULL
.	NULL

1492	NULL
IL-2	NULL
Octamer	NULL
Regulation	NULL
by	NULL
Ap-1	NULL
,	NULL
Oct-2	NULL
,	NULL
and	NULL
RAR	NULL
compared	NULL
with	NULL
the	NULL
wild-type	NULL
receptor	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
OAP/OCT	NULL
-tk-CAT	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CMV-Oct-2	NULL
cotransfected	NULL
into	NULL
an	NULL
RA-resistant	NULL
Jurkat	NULL
subclone	NULL
.	NULL

Truncation	NULL
of	NULL
the	NULL
NH	NULL
;	NULL
terminus	NULL
of	NULL
the	NULL
receptor	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
inhibitory	NULL
activity	NULL
on	NULL
OAP/OCT-tk-CAT	NULL
expression	NULL
and	NULL
only	NULL
slightly	NULL
decreased	NULL
the	NULL
RA-induced	NULL
activation	NULL
of	NULL
TREp2-CAT	NULL
reporter	NULL
,	NULL
carrying	NULL
an	NULL
RA-responsive	NULL
element	NULL
driving	NULL
CAT	NULL
gene	NULL
transcription	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
deletion	NULL
of	NULL
the	NULL
receptor	NULL
DNA-binding	NULL
domain	NULL
significantly	NULL
reduced	NULL
both	NULL
RA-mediated	NULL
repression	NULL
of	NULL
the	NULL
TPA	NULL
/ionomycin-induced	NULL
activation	NULL
of	NULL
OAP/OCT-tk-CAT	NULL
and	NULL
enhancement	NULL
of	NULL
TREp2CAT	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
direct	NULL
DNA	NULL
binding	NULL
of	NULL
RARa	NULL
to	NULL
the	NULL
IL-2	NULL
sequences	NULL
may	NULL
be	NULL
required	NULL
for	NULL
the	NULL
effect	NULL
on	NULL
OAP/OCT	NULL
cis-regulatory	NULL
function	NULL
.	NULL

To	NULL
address	NULL
this	NULL
point	NULL
further	NULL
,	NULL
we	NULL
tested	NULL
the	NULL
ability	NULL
of	NULL
in	NULL
vitro	NULL
syn-thesized	NULL
,	NULL
or	NULL
bacterially	NULL
expressed	NULL
,	NULL
recombinant	NULL
RARa	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
-96	NULL
to	NULL
-66-bp	NULL
OAP/OCT	NULL
IL-2	NULL
sequences	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
RAREB	NULL
.	NULL

According	NULL
to	NULL
data	NULL
previously	NULL
reported	NULL
(	NULL
55	NULL
,	NULL
56	NULL
)	NULL
,	NULL
RARa	NULL
protein	NULL
acquired	NULL
RARE	NULL
DNA-binding	NULL
activity	NULL
after	NULL
complementation	NULL
with	NULL
in	NULL
vitro	NULL
synthesized	NULL
RXRa	NULL
:	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
receptor	NULL
in	NULL
the	NULL
complex	NULL
with	NULL
RARES	NULL
was	NULL
confirmed	NULL
by	NULL
use	NULL
of	NULL
an	NULL
anti-RAR	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
C	NULL
,	NULL
left	NULL
panel	NULL
)	NULL
,	NULL
lanes	NULL
4	NULL
,	NULL
6	NULL
,	NULL
and	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
complementation	NULL
of	NULL
RAR	NULL
with	NULL
nuclear	NULL
extract	NULL
from	NULL
both	NULL
untreated	NULL
or	NULL
TPA	NULL
/ionomycin-activated	NULL
Jurkat	NULL
cells	NULL
also	NULL
conferred	NULL
a	NULL
distinct	NULL
pattern	NULL
of	NULL
DNA-binding	NULL
activity	NULL
,	NULL
which	NULL
was	NULL
supershifted	NULL
by	NULL
the	NULL
anti-RAR	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
C	NULL
,	NULL
left	NULL
panel	NULL
,	NULL
lanes	NULL
9	NULL
,	NULL
11	NULL
,	NULL
and	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
suggested	NULL
that	NULL
,	NULL
in	NULL
nuclear	NULL
extracts	NULL
,	NULL
different	NULL
cofactors	NULL
were	NULL
present	NULL
that	NULL
cooperate	NULL
with	NULL
receptor	NULL
for	NULL
DNA	NULL
binding	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
complementation	NULL
with	NULL
either	NULL
RXRax	NULL
or	NULL
these	NULL
different	NULL
putative	NULL
cofactors	NULL
present	NULL
in	NULL
nuclear	NULL
extract	NULL
from	NULL
both	NULL
untreated	NULL
or	NULL
TPA	NULL
/ionomycin-activated	NULL
Jurkat	NULL
cells	NULL
was	NULL
unable	NULL
to	NULL
confer	NULL
the	NULL
in	NULL
vitro	NULL
OAP/OCT	NULL
motif	NULL
DNA-binding	NULL
ability	NULL
to	NULL
synthesized	NULL
or	NULL
bacterially	NULL
expressed	NULL
RARa	NULL
proteins	NULL
over	NULL
a	NULL
range	NULL
of	NULL
salt	NULL
concentrations	NULL
or	NULL
DNA-binding	NULL
incubation	NULL
conditions	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
C	NULL
,	NULL
right	NULL
panel	NULL
,	NULL
lanes	NULL
5	NULL
,	NULL
6	NULL
,	NULL
and	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
OAP/OCT	NULL
motif	NULL
was	NULL
only	NULL
capable	NULL
of	NULL
forming	NULL
a	NULL
complex	NULL
C	NULL
a	NULL
-	NULL
&	NULL
[	NULL
es	NULL
A	NULL
C	NULL
0-22	NULL
<	NULL
&	NULL
_	NULL
&	NULL
<	NULL
D	NULL
a	NULL
os	NULL
os	NULL
gift-2	NULL
4	NULL
<	NULL
&	NULL
so	NULL
C	NULL
m	NULL
#	NULL
-	NULL
s	NULL
C	NULL
p	NULL
4	NULL
8	NULL
:	NULL
:	NULL
;	NULL
;	NULL
+0	NULL
+	NULL
+	NULL
b	NULL
%	NULL
0	NULL
%	NULL
+	NULL
8	NULL
&	NULL
coc	NULL
&	NULL
&	NULL
x	NULL
soos	NULL
®	NULL
.	NULL

&	NULL
ub	NULL
u	NULL
)	NULL
u	NULL
u	NULL
4	NULL
£	NULL
io	NULL
fff	NULL
Rou	NULL
ut	NULL
t	NULL
rt	NULL
:	NULL
Coan	NULL
.	NULL

(	NULL
Sim	NULL
.	NULL

x	NULL
<	NULL
<	NULL
<	NULL
<	NULL
<	NULL
Z	NULL
+0	NULL
%	NULL
+	NULL
+	NULL
+	NULL
&	NULL
T	NULL
fot	NULL
tf	NULL
tm	NULL
-	NULL
C	NULL
C	NULL
C	NULL
Cog	NULL
a	NULL
#	NULL
2	NULL
@	NULL
£	NULL
a	NULL
G6	NULL
&	NULL
e	NULL
&	NULL
Go	NULL
dw	NULL
$	NULL
o	NULL
d	NULL
&	NULL
€	NULL
coc	NULL
c	NULL
c	NULL
&	NULL
&	NULL
&	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
oo	NULL
cid	NULL
o	NULL
o	NULL
200	NULL
«	NULL
=C	NULL
E	NULL
f	NULL
KG	NULL
f	NULL
f	NULL
f	NULL
:	NULL
z	NULL
z	NULL
z	NULL
z	NULL
Z	NULL
s	NULL
c	NULL
c	NULL
&	NULL
C	NULL
C	NULL
&	NULL
&	NULL
C	NULL
&	NULL
97	NULL
-	NULL
102	NULL
3	NULL
4	NULL
50	NULL
60	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
1	NULL
2	NULL
3	NULL
4	NULL
50	NULL
60	NULL
7	NULL
8	NULL
9	NULL
69	NULL
Me	NULL
#	NULL
OAP	NULL
=-a6	NULL
-	NULL
p	NULL
e	NULL
p	NULL
p	NULL
’	NULL
Octi=	NULL
@	NULL
@	NULL
..	NULL
Oct1	NULL
=-30-	NULL
>	NULL
.	NULL

l	NULL
>	NULL
'	NULL
>	NULL
B	NULL
E	NULL
;	NULL
%	NULL
&	NULL
200	NULL
97	NULL
69	NULL
<	NULL
»	NULL
C	NULL
I	NULL
“	NULL
L	NULL
‘	NULL
u	NULL
‘	NULL
ll	NULL
ih	NULL
(	NULL
Aaa	NULL
.	NULL

ki	NULL
:	NULL
#	NULL
b	NULL
&	NULL
as	NULL
1a	NULL
probes	NULL
:	NULL
RARE	NULL
|	NULL
}	NULL
OaAP/0CT	NULL
oaP/0CT	NULL
Figure	NULL
8	NULL
.	NULL

-	NULL
RARa	NULL
does	NULL
not	NULL
bind	NULL
the	NULL
OAP/OCT	NULL
motif	NULL
but	NULL
inhibits	NULL
OAP-binding	NULL
activity	NULL
in	NULL
vitro	NULL
.	NULL

(	NULL
4	NULL
)	NULL
SDS-PAGE	NULL
of	NULL
[	NULL
*SJmethionine-labeled	NULL
RXRa	NULL
and	NULL
RARa	NULL
translated	NULL
by	NULL
RRL	NULL
(	NULL
RRL	NULL
+	NULL
RXRa	NULL
or	NULL
RRL	NULL
+	NULL
RARa	NULL
)	NULL
or	NULL
unprogrammed	NULL
RRL	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Western	NULL
immunoblotting	NULL
of	NULL
purified	NULL
bacterially	NULL
expressed	NULL
RAR	NULL
protein	NULL
or	NULL
the	NULL
same	NULL
amount	NULL
of	NULL
mock	NULL
bacterial	NULL
lysate	NULL
.	NULL

(	NULL
C	NULL
)	NULL
DNA-binding	NULL
ability	NULL
(	NULL
solid	NULL
arrowheads	NULL
)	NULL
of	NULL
in	NULL
vitro	NULL
synthesized	NULL
RARa	NULL
«	NULL
alone	NULL
or	NULL
complemented	NULL
with	NULL
either	NULL
RXR	NULL
(	NULL
lane	NULL
4	NULL
in	NULL
left	NULL
panel	NULL
and	NULL
lane	NULL
5	NULL
in	NULL
right	NULL
panel	NULL
)	NULL
or	NULL
nuclear	NULL
extract	NULL
(	NULL
N.E	NULL
.	NULL

;	NULL
lane	NULL
9	NULL
in	NULL
left	NULL
panel	NULL
and	NULL
lane	NULL
6	NULL
in	NULL
right	NULL
panel	NULL
)	NULL
from	NULL
untreated	NULL
Jurkat	NULL
cells	NULL
,	NULL
Binding	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
using	NULL
either	NULL
labeled	NULL
RAREA	NULL
(	NULL
5-GATCCGGGTAGGGTTCACCGAAAGTTC-ACTCGA-3	NULL
'	NULL
)	NULL
(	NULL
left	NULL
panel	NULL
)	NULL
or	NULL
II	NULL
>	NULL
2-OAP/OCT	NULL
(	NULL
right	NULL
panel	NULL
)	NULL
oligonucleotides	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
(	NULL
left	NULL
panel	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
13	NULL
;	NULL
right	NULL
panel	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
of	NULL
a	NULL
50-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
probe	NULL
as	NULL
self-competitor	NULL
(	NULL
sc	NULL
.	NULL
)	NULL

.	NULL

Protein	NULL
complexes	NULL
with	NULL
either	NULL
labeled	NULL
RAREA	NULL
or	NULL
IL-	NULL
2-OAP/OCT	NULL
probes	NULL
after	NULL
addition	NULL
of	NULL
anti-RARa	NULL
«	NULL
(	NULL
@	NULL
-RAR	NULL
)	NULL
(	NULL
left	NULL
panel	NULL
,	NULL
lanes	NULL
6	NULL
and	NULL
11	NULL
;	NULL
right	NULL
panel	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
or	NULL
anti-G-galactosidase	NULL
(	NULL
x-Bgal	NULL
)	NULL
,	NULL
(	NULL
left	NULL
panel	NULL
,	NULL
lanes	NULL
7	NULL
and	NULL
12	NULL
;	NULL
right	NULL
panel	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
antibodies	NULL
to	NULL
the	NULL
binding	NULL
reactions	NULL
are	NULL
also	NULL
shown	NULL
(	NULL
open	NULL
arrowheads	NULL
)	NULL
.	NULL

The	NULL
binding	NULL
of	NULL
RXRa	NULL
«	NULL
alone	NULL
or	NULL
unprogrammed	NULL
RRL	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
nuclear	NULL
extract	NULL
is	NULL
also	NULL
represented	NULL
.	NULL

The	NULL
specific	NULL
complex	NULL
between	NULL
nuclear	NULL
extract	NULL
and	NULL
the	NULL
OAP/OCT	NULL
probe	NULL
is	NULL
represented	NULL
by	NULL
Oct-1	NULL
(	NULL
arrow	NULL
)	NULL
.	NULL

(	NULL
D	NULL
)	NULL
RAR	NULL
«	NULL
inhibits	NULL
OAP	NULL
binding	NULL
in	NULL
vitro	NULL
.	NULL

Nuclear	NULL
extracts	NULL
of	NULL
TPA	NULL
/ionomycin-stimulated	NULL
Jurkat	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
labeled	NULL
OAP/OCT	NULL
probe	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
increasing	NULL
amounts	NULL
(	NULL
1-6	NULL
pl	NULL
)	NULL
of	NULL
bacterially	NULL
expressed	NULL
RAR	NULL
«	NULL
(	NULL
lanes	NULL
5-7	NULL
)	NULL
or	NULL
the	NULL
same	NULL
amounts	NULL
of	NULL
mock	NULL
bacterial	NULL
lysate	NULL
(	NULL
lanes	NULL
2-4	NULL
)	NULL
.	NULL

Arrowheads	NULL
indicate	NULL
the	NULL
Oct-1	NULL
complex	NULL
alone	NULL
or	NULL
the	NULL
combined	NULL
OAP/Oct-1	NULL
(	NULL
OAP	NULL
)	NULL
supershifted	NULL
complex	NULL
.	NULL

1493	NULL
de	NULL
Grazia	NULL
et	NULL
al	NULL
.	NULL

that	NULL
included	NULL
the	NULL
Oct-1	NULL
factor	NULL
present	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
either	NULL
untreated	NULL
or	NULL
TPA	NULL
/ionomycin	NULL
activated	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
RAR	NULL
,	NULL
as	NULL
confirmed	NULL
by	NULL
its	NULL
insensitivity	NULL
to	NULL
anti-RAR	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
C	NULL
,	NULL
right	NULL
panel	NULL
,	NULL
lane	NULL
9	NULL
and	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
recombinant	NULL
RARa	NULL
«	NULL
inhibited	NULL
the	NULL
amount	NULL
of	NULL
the	NULL
supershifted	NULL
complex	NULL
formed	NULL
by	NULL
OAP	NULL
and	NULL
Oct-1	NULL
nuclear	NULL
factors	NULL
and	NULL
the	NULL
OAP/OCT	NULL
DNA	NULL
motif	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
D	NULL
,	NULL
lanes	NULL
5-7	NULL
)	NULL
.	NULL

The	NULL
complex	NULL
formed	NULL
by	NULL
nuclear	NULL
Oct-1	NULL
alone	NULL
and	NULL
DNA	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
RARa	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
D	NULL
)	NULL
.	NULL

Mock-transformed	NULL
bacterial	NULL
lysate	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
formation	NULL
of	NULL
either	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
D	NULL
,	NULL
lanes	NULL
2-4	NULL
)	NULL
.	NULL

Discussion	NULL
Jun	NULL
and	NULL
fos	NULL
Participate	NULL
in	NULL
the	NULL
OAP	NULL
Octamer	NULL
Complex	NULL
and	NULL
Cooperate	NULL
with	NULL
Oct-2	NULL
for	NULL
Transacting	NULL
Function	NULL
.	NULL

-	NULL
We	NULL
report	NULL
here	NULL
that	NULL
Oct-2	NULL
is	NULL
a	NULL
very	NULL
weak	NULL
transactivator	NULL
of	NULL
the	NULL
IL-2	NULL
octamer	NULL
motif	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
phorbol	NULL
ester	NULL
and	NULL
calcium	NULL
ionophore	NULL
,	NULL
despite	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
active	NULL
transcriptional	NULL
activation	NULL
domain	NULL
.	NULL

This	NULL
would	NULL
suggest	NULL
a	NULL
requirement	NULL
for	NULL
both	NULL
PKC-	NULL
and	NULL
calcium-induced	NULL
coregulatory	NULL
signals	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
requirement	NULL
of	NULL
coregulatory	NULL
signals	NULL
for	NULL
Oct-2	NULL
transcriptional	NULL
activity	NULL
has	NULL
also	NULL
been	NULL
recently	NULL
reported	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

These	NULL
signals	NULL
,	NULL
which	NULL
are	NULL
specific	NULL
for	NULL
B	NULL
cells	NULL
and	NULL
absent	NULL
in	NULL
HeLa	NULL
cells	NULL
,	NULL
appear	NULL
to	NULL
be	NULL
accounted	NULL
for	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
OCA-B	NULL
factors	NULL
,	NULL
which	NULL
interact	NULL
with	NULL
Oct-2	NULL
(	NULL
57	NULL
)	NULL
.	NULL

Similar	NULL
data	NULL
have	NULL
also	NULL
been	NULL
reported	NULL
for	NULL
EAA	NULL
,	NULL
which	NULL
provides	NULL
transcription	NULL
activation	NULL
function	NULL
to	NULL
Oct-4	NULL
via	NULL
protein-protein	NULL
interaction	NULL
in	NULL
embryonic	NULL
stem	NULL
cells	NULL
{	NULL
58	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
transactivation	NULL
properties	NULL
of	NULL
Oct-2	NULL
and	NULL
Oct-4	NULL
appear	NULL
to	NULL
result	NULL
from	NULL
the	NULL
ability	NULL
of	NULL
specific	NULL
cell	NULL
types	NULL
to	NULL
provide	NULL
cooperating	NULL
factors	NULL
that	NULL
give	NULL
them	NULL
functional	NULL
competence	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
these	NULL
recently	NULL
identified	NULL
coactivators	NULL
,	NULL
we	NULL
report	NULL
here	NULL
that	NULL
another	NULL
of	NULL
the	NULL
cell-specific	NULL
factors	NULL
that	NULL
can	NULL
cooperate	NULL
with	NULL
Oct-2	NULL
is	NULL
the	NULL
AP-1	NULL
complex	NULL
in	NULL
T	NULL
cells	NULL
We	NULL
suggest	NULL
also	NULL
that	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
AP-1	NULL
factor	NULL
underlies	NULL
the	NULL
requirement	NULL
for	NULL
extracellular	NULL
regulatory	NULL
signals	NULL
(	NULL
PKC	NULL
and	NULL
calcium	NULL
ionophore	NULL
)	NULL
in	NULL
Oct-2-mediated	NULL
transactivation	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
this	NULL
respect	NULL
,	NULL
we	NULL
have	NULL
further	NULL
characterized	NULL
the	NULL
previously	NULL
described	NULL
OAP®	NULL
complex	NULL
,	NULL
which	NULL
binds	NULL
to	NULL
a	NULL
region	NULL
closely	NULL
linked	NULL
to	NULL
the	NULL
octamer	NULL
motif	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
29	NULL
)	NULL
as	NULL
containing	NULL
an	NULL
AP-1	NULL
complex	NULL
.	NULL

Our	NULL
data	NULL
confirm	NULL
the	NULL
recently	NULL
reported	NULL
presence	NULL
of	NULL
jun	NULL
in	NULL
the	NULL
OAP®	NULL
complex	NULL
(	NULL
30	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
show	NULL
the	NULL
presence	NULL
of	NULL
immunoreactive	NULL
fos	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
in	NULL
the	NULL
OAP®	NULL
complex	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
show	NULL
that	NULL
overexpression	NULL
of	NULL
jun	NULL
and	NULL
fos	NULL
proteins	NULL
cooperate	NULL
with	NULL
Oct-2	NULL
for	NULL
the	NULL
transactivation	NULL
of	NULL
the	NULL
IL-2	NULL
octamer	NULL
motif	NULL
,	NULL
and	NULL
that	NULL
this	NULL
cooperation	NULL
is	NULL
strictly	NULL
required	NULL
for	NULL
full	NULL
enhancer	NULL
activity	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
an	NULL
active	NULL
transcriptional	NULL
activation	NULL
domain	NULL
within	NULL
Oct-2	NULL
suggests	NULL
that	NULL
the	NULL
ability	NULL
of	NULL
AP-1	NULL
and	NULL
other	NULL
coregulatory	NULL
factors	NULL
to	NULL
impart	NULL
functional	NULL
transcriptional	NULL
competence	NULL
to	NULL
Oct-2	NULL
does	NULL
not	NULL
simply	NULL
provide	NULL
a	NULL
transcriptional	NULL
domain	NULL
for	NULL
a	NULL
protein	NULL
that	NULL
lacks	NULL
it	NULL
,	NULL
as	NULL
in	NULL
the	NULL
case	NULL
of	NULL
VP16-Oct-1	NULL
interactions	NULL
(	NULL
13	NULL
,	NULL
33	NULL
)	NULL
.	NULL

We	NULL
have	NULL
mapped	NULL
a	NULL
part	NULL
of	NULL
the	NULL
TPA	NULL
/calcium-induced	NULL
transacting	NULL
function	NULL
of	NULL
Oct-2	NULL
to	NULL
the	NULL
COOH	NULL
terminus	NULL
,	NULL
a	NULL
region	NULL
rich	NULL
in	NULL
heptad	NULL
leucine	NULL
repeats	NULL
with	NULL
the	NULL
potential	NULL
to	NULL
form	NULL
a	NULL
``	NULL
leucine	NULL
zipper	NULL
-like	NULL
structure	NULL
.	NULL

It	NULL
remains	NULL
to	NULL
be	NULL
elucidated	NULL
whether	NULL
this	NULL
region	NULL
is	NULL
capable	NULL
if	NULL
interacting	NULL
with	NULL
leucine	NULL
zipper	NULL
1494	NULL
regions	NULL
in	NULL
jun	NULL
and	NULL
fos	NULL
proteins	NULL
.	NULL

We	NULL
also	NULL
observed	NULL
differential	NULL
transactivation	NULL
of	NULL
the	NULL
OAP	NULL
cis-element	NULL
by	NULL
distinct	NULL
members	NULL
of	NULL
the	NULL
jun	NULL
and	NULL
fos	NULL
family	NULL
,	NULL
with	NULL
jun-B	NULL
and	NULL
Fos-B	NULL
being	NULL
the	NULL
most	NULL
active	NULL
.	NULL

The	NULL
composition	NULL
of	NULL
the	NULL
AP-1	NULL
factors	NULL
cooperating	NULL
with	NULL
distinct	NULL
transacting	NULL
factors	NULL
,	NULL
such	NULL
as	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
,	NULL
may	NULL
therefore	NULL
by	NULL
influential	NULL
in	NULL
determining	NULL
the	NULL
transacting	NULL
function	NULL
of	NULL
the	NULL
final	NULL
complex	NULL
.	NULL

This	NULL
may	NULL
explain	NULL
the	NULL
different	NULL
transactivating	NULL
function	NULL
of	NULL
jun-B	NULL
reported	NULL
in	NULL
this	NULL
study	NULL
compared	NULL
with	NULL
that	NULL
described	NULL
previously	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Such	NULL
a	NULL
selection	NULL
for	NULL
AP-1	NULL
complexes	NULL
of	NULL
different	NULL
composition	NULL
has	NULL
previously	NULL
been	NULL
described	NULL
for	NULL
AP-1	NULL
cooperation	NULL
with	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NFAT	NULL
)	NULL
motif	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer	NULL
(	NULL
59-61	NULL
)	NULL
.	NULL

RARa	NULL
Impairs	NULL
the	NULL
Oct-2-dependent	NULL
AP-1/OAP	NULL
Function	NULL
.	NULL

Mapping	NULL
of	NULL
the	NULL
Oct-2	NULL
domains	NULL
required	NULL
for	NULL
TPA/calcium-induced	NULL
activation	NULL
function	NULL
revealed	NULL
that	NULL
they	NULL
overlapped	NULL
the	NULL
region	NULL
required	NULL
for	NULL
negative	NULL
regulation	NULL
by	NULL
RARa	NULL
«	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
a	NULL
focus	NULL
for	NULL
both	NULL
activator	NULL
and	NULL
inhibitor	NULL
signals	NULL
may	NULL
occur	NULL
on	NULL
a	NULL
unique	NULL
pathway	NULL
.	NULL

We	NULL
show	NULL
here	NULL
that	NULL
this	NULL
pathway	NULL
could	NULL
be	NULL
represented	NULL
by	NULL
the	NULL
AP-1	NULL
complex	NULL
.	NULL

Abrogation	NULL
of	NULL
AP-1	NULL
binding	NULL
to	NULL
the	NULL
OAP	NULL
cis-element	NULL
blunted	NULL
the	NULL
antagonistic	NULL
activity	NULL
of	NULL
RAR	NULL
.	NULL

An	NULL
indirect	NULL
modulation	NULL
of	NULL
IL-2	NULL
promoter	NULL
by	NULL
RAR	NULL
on	NULL
AP-1/OAP	NULL
function	NULL
was	NULL
suggested	NULL
by	NULL
the	NULL
requirement	NULL
for	NULL
the	NULL
receptor	NULL
DNA-binding	NULL
domain	NULL
but	NULL
not	NULL
direct	NULL
in	NULL
vitro	NULL
binding	NULL
to	NULL
the	NULL
IL-2	NULL
octamer	NULL
motif	NULL
and	NULL
by	NULL
the	NULL
ability	NULL
of	NULL
RARa	NULL
«	NULL
to	NULL
inhibit	NULL
the	NULL
AP-1	NULL
binding	NULL
activity	NULL
to	NULL
the	NULL
IL-2-OAP/OCT	NULL
sequence	NULL
in	NULL
vitro	NULL
.	NULL

A	NULL
similar	NULL
mechanism	NULL
has	NULL
been	NULL
proposed	NULL
for	NULL
RAR	NULL
antagonism	NULL
of	NULL
collagenase	NULL
AP-1	NULL
cis-element	NULL
by	NULL
an	NULL
inhibition	NULL
of	NULL
the	NULL
AP-1	NULL
complex	NULL
DNA-binding	NULL
activity	NULL
in	NULL
HeLa	NULL
cells	NULL
independently	NULL
from	NULL
direct	NULL
RAR	NULL
binding	NULL
to	NULL
DNA	NULL
(	NULL
18	NULL
,	NULL
19	NULL
,	NULL
62	NULL
)	NULL
.	NULL

We	NULL
used	NULL
a	NULL
similar	NULL
model	NULL
to	NULL
demonstrate	NULL
inhibition	NULL
of	NULL
TPA-induced	NULL
activation	NULL
of	NULL
collagenase	NULL
AP-1	NULL
cis-regulatory	NULL
activity	NULL
by	NULL
RARa	NULL
«	NULL
x	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Therefore	NULL
,	NULL
although	NULL
the	NULL
in	NULL
vivo	NULL
binding	NULL
of	NULL
RAR	NULL
to	NULL
the	NULL
OAP/OCT	NULL
motif	NULL
can	NULL
not	NULL
be	NULL
ruled	NULL
out	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
receptor	NULL
to	NULL
inhibit	NULL
the	NULL
OAP	NULL
binding	NULL
activity	NULL
without	NULL
direct	NULL
DNA	NULL
binding	NULL
in	NULL
vitro	NULL
,	NULL
presented	NULL
here	NULL
,	NULL
is	NULL
sufficient	NULL
to	NULL
suggest	NULL
that	NULL
RAR	NULL
inhibits	NULL
the	NULL
functional	NULL
synergism	NULL
between	NULL
AP-1	NULL
and	NULL
Oct	NULL
factors	NULL
by	NULL
preventing	NULL
the	NULL
binding	NULL
of	NULL
jun	NULL
and	NULL
fos	NULL
to	NULL
the	NULL
OAP	NULL
binding	NULL
site	NULL
.	NULL

An	NULL
appropriate	NULL
genetic	NULL
context	NULL
for	NULL
AP-1	NULL
regulation	NULL
seems	NULL
to	NULL
be	NULL
required	NULL
,	NULL
as	NULL
RA	NULL
does	NULL
not	NULL
interfere	NULL
with	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
AP-1	NULL
complex	NULL
found	NULL
in	NULL
the	NULL
NFAT	NULL
element	NULL
of	NULL
IL-2	NULL
enhancer	NULL
(	NULL
23	NULL
,	NULL
63	NULL
)	NULL
.	NULL

Our	NULL
data	NULL
leave	NULL
open	NULL
,	NULL
however	NULL
,	NULL
the	NULL
question	NULL
of	NULL
the	NULL
potential	NULL
contribution	NULL
of	NULL
Oct	NULL
factors	NULL
in	NULL
the	NULL
negative	NULL
regulation	NULL
of	NULL
AP-1	NULL
sites	NULL
by	NULL
RAR	NULL
and	NULL
their	NULL
potential	NULL
interaction	NULL
with	NULL
the	NULL
receptor	NULL
.	NULL

In	NULL
this	NULL
respect	NULL
,	NULL
it	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
protein-protein	NULL
interactions	NULL
have	NULL
been	NULL
implicated	NULL
in	NULL
both	NULL
the	NULL
antagonism	NULL
of	NULL
Oct-2	NULL
function	NULL
by	NULL
glucocorticoid	NULL
receptor	NULL
(	NULL
GR	NULL
;	NULL
64	NULL
)	NULL
and	NULL
the	NULL
synergism	NULL
between	NULL
GR	NULL
and	NULL
Oct-1	NULL
(	NULL
65	NULL
)	NULL
.	NULL

It	NULL
is	NULL
of	NULL
further	NULL
interest	NULL
that	NULL
the	NULL
repression	NULL
of	NULL
the	NULL
IL-2-OAP/	NULL
OCT	NULL
motif	NULL
by	NULL
RA	NULL
,	NULL
described	NULL
here	NULL
,	NULL
is	NULL
not	NULL
without	NULL
similarity	NULL
to	NULL
a	NULL
recent	NULL
report	NULL
describing	NULL
RAR-mediated	NULL
interference	NULL
with	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
calcitonin/calcitonin	NULL
gene-related	NULL
peptide	NULL
enhancer	NULL
by	NULL
cell-specific	NULL
helix-loop-helix	NULL
and	NULL
octamer	NULL
proteins	NULL
in	NULL
combination	NULL
(	NULL
66	NULL
)	NULL
.	NULL

Another	NULL
nuclear	NULL
receptor	NULL
(	NULL
GR	NULL
)	NULL
has	NULL
been	NULL
described	NULL
to	NULL
cause	NULL
a	NULL
similar	NULL
impairment	NULL
of	NULL
the	NULL
functional	NULL
cooperation	NULL
between	NULL
distinct	NULL
cis-elements	NULL
(	NULL
AP-1	NULL
and	NULL
NFAT	NULL
)	NULL
in	NULL
the	NULL
IL-2	NULL
enhancer	NULL
(	NULL
21	NULL
)	NULL
.	NULL

II:2	NULL
Octamer	NULL
Regulation	NULL
by	NULL
Ap-1	NULL
,	NULL
Oct-2	NULL
,	NULL
and	NULL
RAR	NULL
Multiple	NULL
Pathways	NULL
of	NULL
AP-1	NULL
Regulation	NULL
:	NULL
Implications	NULL
for	NULL
T	NULL
Cell	NULL
Development	NULL
.	NULL

-	NULL
Octamer-binding	NULL
proteins	NULL
containing	NULL
homeo-domains	NULL
are	NULL
developmentally	NULL
regulated	NULL
and	NULL
involved	NULL
in	NULL
the	NULL
cascade	NULL
of	NULL
events	NULL
controlling	NULL
morphogenic	NULL
processes	NULL
(	NULL
14	NULL
)	NULL
.	NULL

As	NULL
RA	NULL
regulates	NULL
octamer-binding	NULL
proteins	NULL
(	NULL
9-12	NULL
)	NULL
and	NULL
IL-2	NULL
is	NULL
active	NULL
in	NULL
T	NULL
cell	NULL
development	NULL
(	NULL
25	NULL
,	NULL
26	NULL
)	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
RAR	NULL
and	NULL
octamer-binding	NULL
factors	NULL
might	NULL
combine	NULL
to	NULL
modulate	NULL
thymocyte	NULL
differentiation	NULL
through	NULL
regulation	NULL
of	NULL
cytokine	NULL
gene	NULL
transcription	NULL
.	NULL

This	NULL
hypothesis	NULL
is	NULL
consistent	NULL
with	NULL
our	NULL
observation	NULL
that	NULL
RA	NULL
can	NULL
modulate	NULL
T	NULL
cell	NULL
precursor	NULL
development	NULL
in	NULL
an	NULL
in	NULL
vitro	NULL
thymocyte	NULL
differentiation	NULL
system	NULL
(	NULL
67	NULL
,	NULL
68	NULL
)	NULL
.	NULL

To	NULL
extend	NULL
this	NULL
hypothesis	NULL
,	NULL
the	NULL
data	NULL
described	NULL
here	NULL
and	NULL
elsewhere	NULL
(	NULL
30	NULL
,	NULL
59-61	NULL
,	NULL
63	NULL
)	NULL
suggest	NULL
a	NULL
central	NULL
role	NULL
for	NULL
AP-1	NULL
sites	NULL
in	NULL
the	NULL
functional	NULL
organization	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer	NULL
,	NULL
which	NULL
is	NULL
com	NULL
posed	NULL
of	NULL
several	NULL
regulatory	NULL
modules	NULL
,	NULL
including	NULL
an	NULL
AP-1	NULL
site	NULL
that	NULL
potentially	NULL
cooperates	NULL
with	NULL
another	NULL
closely	NULL
linked	NULL
transacting	NULL
factor-binding	NULL
motif	NULL
.	NULL

This	NULL
site	NULL
may	NULL
well	NULL
be	NULL
responsible	NULL
for	NULL
differential	NULL
regulation	NULL
by	NULL
external	NULL
stimuli	NULL
.	NULL

The	NULL
role	NULL
of	NULL
AP-1	NULL
in	NULL
regulating	NULL
Oct-2	NULL
and	NULL
mediating	NULL
RAR	NULL
activity	NULL
would	NULL
strongly	NULL
suggest	NULL
that	NULL
it	NULL
may	NULL
also	NULL
contribute	NULL
to	NULL
the	NULL
T	NULL
cell	NULL
differentiation	NULL
process	NULL
.	NULL

Support	NULL
for	NULL
this	NULL
comes	NULL
from	NULL
observations	NULL
that	NULL
changes	NULL
in	NULL
the	NULL
AP-1	NULL
pathway	NULL
accompany	NULL
the	NULL
induction	NULL
of	NULL
T	NULL
cell	NULL
tolerance	NULL
(	NULL
69	NULL
)	NULL
and	NULL
thymocyte	NULL
ontogeny	NULL
(	NULL
70	NULL
)	NULL
.	NULL

As	NULL
AP-1	NULL
responds	NULL
to	NULL
a	NULL
broad	NULL
range	NULL
of	NULL
activating	NULL
stimuli	NULL
,	NULL
often	NULL
unrelated	NULL
to	NULL
differentiation	NULL
pathways	NULL
,	NULL
this	NULL
transcription	NULL
factor	NULL
may	NULL
provide	NULL
signals	NULL
that	NULL
specify	NULL
developmental	NULL
programs	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
selective	NULL
functional	NULL
interactions	NULL
with	NULL
differentiation-related	NULL
transacting	NULL
factors	NULL
.	NULL

Drs	NULL
.	NULL

U.	NULL
de	NULL
Grazia	NULL
and	NULL
M.	NULL
P.	NULL
Felli	NULL
were	NULL
equal	NULL
contributors	NULL
to	NULL
the	NULL
work	NULL
presented	NULL
here	NULL
.	NULL

We	NULL
thank	NULL
Drs	NULL
.	NULL

P.	NULL
Angel	NULL
,	NULL
P.	NULL
Chambon	NULL
,	NULL
B.	NULL
Cullen	NULL
,	NULL
R.	NULL
Evans	NULL
,	NULL
N.	NULL
J.	NULL
Holbrook	NULL
,	NULL
M.	NULL
Iadarola	NULL
,	NULL
M.	NULL
Karin	NULL
,	NULL
W.	NULL
Herr	NULL
,	NULL
R.	NULL
Muller	NULL
,	NULL
D.	NULL
D'Ambrosio	NULL
,	NULL
W.	NULL
Schaffner	NULL
,	NULL
G.	NULL
Schutz	NULL
,	NULL
and	NULL
K.	NULL
Umesono	NULL
for	NULL
kindly	NULL
providing	NULL
plasmids	NULL
,	NULL
anti-fos	NULL
,	NULL
anti-Oct-1	NULL
,	NULL
-Oct-2	NULL
,	NULL
and	NULL
RARa	NULL
«	NULL
antibodies	NULL
.	NULL

We	NULL
are	NULL
grateful	NULL
to	NULL
Drs	NULL
.	NULL

A.	NULL
Hayday	NULL
and	NULL
A.	NULL
MacKay	NULL
for	NULL
critical	NULL
reading	NULL
of	NULL
the	NULL
manuscript	NULL
and	NULL
A.	NULL
Tiberio	NULL
,	NULL
F.	NULL
Duranti	NULL
,	NULL
and	NULL
S.	NULL
Ferraro	NULL
for	NULL
technical	NULL
assistance	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
National	NULL
Research	NULL
Council	NULL
,	NULL
Applicazioni	NULL
Cliniche	NULL
Ricerca	NULL
Oncologica	NULL
(	NULL
ACRO	NULL
)	NULL
Project	NULL
,	NULL
Aging	NULL
Project	NULL
,	NULL
and	NULL
Biotechnology	NULL
and	NULL
Bicinstrumentation	NULL
Project	NULL
,	NULL
the	NULL
As-sociazione	NULL
Italiana	NULL
per	NULL
la	NULL
Ricerca	NULL
sul	NULL
Cancro	NULL
(	NULL
AIRC	NULL
)	NULL
,	NULL
and	NULL
the	NULL
Istituto	NULL
Superiore	NULL
di	NULL
Sanita	NULL
(	NULL
AIDS	NULL
Program	NULL
}	NULL
.	NULL

Address	NULL
correspondence	NULL
to	NULL
Dr.	NULL
Alberto	NULL
Gulino	NULL
,	NULL
Department	NULL
of	NULL
Experimental	NULL
Medicine	NULL
,	NULL
University	NULL
La	NULL
Sapienza	NULL
,	NULL
324	NULL
,	NULL
Viale	NULL
Regina	NULL
Elena	NULL
,	NULL
00161	NULL
,	NULL
Italy	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
28	NULL
February	NULL
1994	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
26	NULL
May	NULL
1994	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Boncinelli	NULL
,	NULL
E.	NULL
,	NULL
A.	NULL
Simeone	NULL
,	NULL
D.	NULL
Acampora	NULL
,	NULL
and	NULL
F.	NULL
Mavilio	NULL
.	NULL

1991	NULL
.	NULL

HOX	NULL
gene	NULL
activation	NULL
by	NULL
retinoic	NULL
acid	NULL
.	NULL

Trends	NULL
Genet	NULL
,	NULL
10:329	NULL
.	NULL

2	NULL
.	NULL

Breitman	NULL
,	NULL
TR	NULL
.	NULL

,	NULL
SE	NULL
.	NULL

Selonick	NULL
,	NULL
and	NULL
S.S.	NULL
Collins	NULL
.	NULL

1980	NULL
.	NULL

Induction	NULL
of	NULL
differentiation	NULL
of	NULL
the	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
cell	NULL
line	NULL
(	NULL
HL60	NULL
)	NULL
by	NULL
retinoic	NULL
acid	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

77:2936	NULL
.	NULL

3	NULL
.	NULL

Campisi	NULL
,	NULL
J.	NULL
,	NULL
H.E	NULL
.	NULL

Gray	NULL
,	NULL
A.B	NULL
.	NULL

Pardee	NULL
,	NULL
M.	NULL
Dean	NULL
,	NULL
and	NULL
G.E	NULL
.	NULL

Sonen-shein	NULL
.	NULL

1984	NULL
.	NULL

Cell-cycle	NULL
control	NULL
of	NULL
c-myc	NULL
but	NULL
not	NULL
c-ras	NULL
expression	NULL
is	NULL
lost	NULL
following	NULL
chemical	NULL
transformation	NULL
.	NULL

Cell	NULL
.	NULL

36:241	NULL
.	NULL

4.	NULL
de	NULL
Groot	NULL
,	NULL
RP	NULL
.	NULL

,	NULL
C.	NULL
Pals	NULL
,	NULL
and	NULL
W.	NULL
Kruijer	NULL
.	NULL

1991	NULL
.	NULL

Transcriptional	NULL
control	NULL
of	NULL
c-jun	NULL
by	NULL
retinoic	NULL
acid	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

19:1585	NULL
.	NULL

5	NULL
.	NULL

Maden	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
C.	NULL
Tickle	NULL
.	NULL

1991	NULL
.	NULL

Retinoic	NULL
acid	NULL
and	NULL
vertebrate	NULL
development	NULL
.	NULL

Seminars	NULL
in	NULL
Developmental	NULL
Biology	NULL
.	NULL

2:151	NULL
.	NULL

6	NULL
.	NULL

Mille	NULL
,	NULL
W.H	NULL
.	NULL

,	NULL
Jr.	NULL
,	NULL
D.	NULL
May	NULL
,	NULL
A.	NULL
Li	NULL
,	NULL
J.F	NULL
.	NULL

Grippo	NULL
,	NULL
and	NULL
E.	NULL
Dmitrovsky	NULL
.	NULL

1990	NULL
.	NULL

Retinoic	NULL
acid	NULL
induces	NULL
down-regulation	NULL
of	NULL
several	NULL
growth	NULL
factors	NULL
and	NULL
protooncogenes	NULL
in	NULL
a	NULL
human	NULL
embri-onal	NULL
cancer	NULL
cell	NULL
line	NULL
.	NULL

Oncogene	NULL
.	NULL

5:511	NULL
.	NULL

7	NULL
.	NULL

Strickland	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
M.	NULL
Mahadavi	NULL
.	NULL

1978	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
differentiation	NULL
in	NULL
teratocarcinoma	NULL
stem	NULL
cells	NULL
by	NULL
retinoic	NULL
acid	NULL
.	NULL

Cell	NULL
.	NULL

15:393	NULL
.	NULL

8	NULL
.	NULL

Leid	NULL
,	NULL
M.	NULL
,	NULL
P.	NULL
Kastner	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1992	NULL
.	NULL

Multiplicity	NULL
generates	NULL
diversity	NULL
in	NULL
the	NULL
retinoic	NULL
acid	NULL
signalling	NULL
pathways	NULL
.	NULL

Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

17:427	NULL
.	NULL

9	NULL
.	NULL

Chellappan	NULL
,	NULL
S.P	NULL
.	NULL

,	NULL
and	NULL
J.R.	NULL
Nevins	NULL
.	NULL

1990	NULL
.	NULL

DNA	NULL
octamer	NULL
element	NULL
can	NULL
confer	NULL
E1A	NULL
transactivation	NULL
and	NULL
adenovirus	NULL
infection	NULL
results	NULL
in	NULL
a	NULL
stimulation	NULL
fo	NULL
the	NULL
DNA-binding	NULL
activity	NULL
of	NULL
OTF-	NULL
1495	NULL
de	NULL
Grazia	NULL
et	NULL
al	NULL
.	NULL

1/NFIII	NULL
factor	NULL
.	NULL

Proc	NULL
Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

87:5878	NULL
.	NULL

10	NULL
.	NULL

Okazawa	NULL
,	NULL
H.	NULL
,	NULL
K.	NULL
Okamoto	NULL
,	NULL
F.	NULL
Ishino	NULL
,	NULL
T.	NULL
Ishino-Kaneko	NULL
,	NULL
S.	NULL
Takeda	NULL
,	NULL
Y.	NULL
Toyoda	NULL
,	NULL
M.	NULL
Muramatsu	NULL
,	NULL
and	NULL
H.	NULL
Hamada	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
oct3	NULL
gene	NULL
,	NULL
a	NULL
gene	NULL
for	NULL
an	NULL
embryonic	NULL
transcription	NULL
factor	NULL
,	NULL
is	NULL
controlled	NULL
by	NULL
a	NULL
retinoic	NULL
acid	NULL
repressible	NULL
enhancer	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

10:2997	NULL
.	NULL

11	NULL
.	NULL

Rosner	NULL
,	NULL
M.H	NULL
.	NULL

,	NULL
M.A	NULL
.	NULL

Vigano	NULL
,	NULL
K.	NULL
Ozato	NULL
,	NULL
P.M.	NULL
Timmons	NULL
,	NULL
F.	NULL
Poirier	NULL
,	NULL
PW.J	NULL
.	NULL

Rigby	NULL
,	NULL
and	NULL
L.	NULL
Staudt	NULL
.	NULL

1990	NULL
.	NULL

A	NULL
POU-domain	NULL
transcription	NULL
factor	NULL
in	NULL
early	NULL
stem	NULL
cells	NULL
and	NULL
germ	NULL
cells	NULL
of	NULL
the	NULL
mammalian	NULL
embryo	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

345:686	NULL
.	NULL

12	NULL
.	NULL

Scholer	NULL
,	NULL
H.R	NULL
.	NULL

,	NULL
R.	NULL
Balling	NULL
,	NULL
A.K	NULL
.	NULL

Hatzopoulos	NULL
,	NULL
N.	NULL
Suzuki	NULL
,	NULL
and	NULL
P.	NULL
Gruss	NULL
.	NULL

1989	NULL
.	NULL

Octamer	NULL
binding	NULL
proteins	NULL
confer	NULL
transcriptional	NULL
activity	NULL
in	NULL
early	NULL
mouse	NULL
embryogenesis	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

8:2551	NULL
.	NULL

13	NULL
.	NULL

Ruvkun	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
M.	NULL
Finney	NULL
.	NULL

1991	NULL
.	NULL

Regulation	NULL
of	NULL
transcription	NULL
and	NULL
cell	NULL
identity	NULL
by	NULL
POU	NULL
domain	NULL
proteins	NULL
.	NULL

Cell	NULL
.	NULL

64:475	NULL
.	NULL

14	NULL
.	NULL

Scholer	NULL
,	NULL
H.R	NULL
.	NULL

1991	NULL
.	NULL

Octamania	NULL
:	NULL
the	NULL
POU	NULL
factors	NULL
in	NULL
murine	NULL
development	NULL
.	NULL

Trends	NULL
Genet	NULL
.	NULL

7:323	NULL
.	NULL

15	NULL
.	NULL

Desbois	NULL
,	NULL
C.	NULL
,	NULL
D.	NULL
Aubert	NULL
,	NULL
C.	NULL
Legrand	NULL
,	NULL
B	NULL
.	NULL

Pain	NULL
,	NULL
and	NULL
J.	NULL
Samarut	NULL
.	NULL

1991	NULL
.	NULL

A	NULL
novel	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
v-ErbA	NULL
:	NULL
abrogation	NULL
of	NULL
the	NULL
inactivation	NULL
of	NULL
transcription	NULL
factor	NULL
AP-1	NULL
by	NULL
retinoic	NULL
acid	NULL
and	NULL
thyroid	NULL
hormone	NULL
receptors	NULL
.	NULL

Cell	NULL
.	NULL

67:731	NULL
.	NULL

16	NULL
.	NULL

Diamond	NULL
,	NULL
M.LI	NULL
.	NULL

,	NULL
J.N	NULL
.	NULL

Miner	NULL
,	NULL
SK	NULL
.	NULL

Yoshinaga	NULL
,	NULL
and	NULL
KR	NULL
.	NULL

Yamamoto	NULL
.	NULL

1990	NULL
.	NULL

Transcription	NULL
factor	NULL
interaction	NULL
:	NULL
selectors	NULL
of	NULL
positive	NULL
or	NULL
negative	NULL
regulation	NULL
from	NULL
a	NULL
single	NULL
DNA	NULL
element	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

249:1266	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

Maroder	NULL
,	NULL
M.	NULL
,	NULL
A.R	NULL
.	NULL

Farina	NULL
,	NULL
A.	NULL
Vacca	NULL
,	NULL
M.P	NULL
.	NULL

Felli	NULL
,	NULL
D.	NULL
Meco	NULL
,	NULL
I.	NULL
Screpanti	NULL
,	NULL
L.	NULL
Frati	NULL
,	NULL
and	NULL
A.	NULL
Gulino	NULL
.	NULL

1993	NULL
.	NULL

Cell-specific	NULL
bifunc-tional	NULL
role	NULL
of	NULL
jun	NULL
oncogene	NULL
family	NULL
members	NULL
on	NULL
glucocorticoid	NULL
receptor-dependent	NULL
transcription	NULL
.	NULL

Mol	NULL
.	NULL

Endocrinol	NULL
.	NULL

7:570	NULL
.	NULL

Nicholson	NULL
,	NULL
R.C	NULL
.	NULL

,	NULL
S.	NULL
Mader	NULL
,	NULL
S.	NULL
Napgal	NULL
,	NULL
M.	NULL
Leid	NULL
,	NULL
C.	NULL
Rochette-Egly	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1990	NULL
.	NULL

Negative	NULL
regulation	NULL
of	NULL
the	NULL
rat	NULL
stromelysin	NULL
gene	NULL
promoter	NULL
by	NULL
retinoic	NULL
acid	NULL
is	NULL
mediated	NULL
by	NULL
an	NULL
AP-1	NULL
binding	NULL
site	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
Mol	NULL
.	NULL

Biol	NULL
Organ	NULL
)	NULL
.	NULL

J	NULL
.	NULL

9:4443	NULL
.	NULL

Schiile	NULL
,	NULL
R.	NULL
,	NULL
P.	NULL
Rangarajan	NULL
,	NULL
N.	NULL
Yang	NULL
,	NULL
S.	NULL
Kliewer	NULL
,	NULL
L.J	NULL
.	NULL

Ransone	NULL
,	NULL
J.	NULL
Bolado	NULL
,	NULL
I.	NULL
M.	NULL
Verma	NULL
,	NULL
and	NULL
R.M	NULL
.	NULL

Evans	NULL
.	NULL

1991	NULL
.	NULL

Retinoic	NULL
acid	NULL
is	NULL
a	NULL
negative	NULL
regulator	NULL
of	NULL
AP-1	NULL
responsive	NULL
genes	NULL
.	NULL

Proc	NULL
Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

88:6092	NULL
.	NULL

Shemshedini	NULL
,	NULL
L	NULL
,	NULL
R.	NULL
Knauthe	NULL
,	NULL
P.	NULL
Sassone-Corsi	NULL
,	NULL
A.	NULL
Pornon	NULL
,	NULL
and	NULL
H.	NULL
Gronemeyer	NULL
,	NULL
1991	NULL
.	NULL

Cell-specific	NULL
inhibitory	NULL
and	NULL
stimula-tory	NULL
effects	NULL
of	NULL
fos	NULL
and	NULL
jun	NULL
on	NULL
transcription	NULL
activation	NULL
by	NULL
nuclear	NULL
receptors	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

10:3839	NULL
.	NULL

Vacca	NULL
,	NULL
A.	NULL
,	NULL
M.P	NULL
.	NULL

Felli	NULL
,	NULL
A.R	NULL
.	NULL

Farina	NULL
,	NULL
S.	NULL
Martinotti	NULL
,	NULL
M.	NULL
Maroder	NULL
,	NULL
I.	NULL
Screpanti	NULL
,	NULL
D.	NULL
Meco	NULL
,	NULL
E.	NULL
Petrangeli	NULL
,	NULL
L.	NULL
Frati	NULL
,	NULL
and	NULL
A.	NULL
Gulino	NULL
.	NULL

1992	NULL
.	NULL

Glucocorticoid	NULL
receptor-mediated	NULL
suppression	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
gene	NULL
expression	NULL
through	NULL
impairment	NULL
of	NULL
the	NULL
cooper-ativity	NULL
between	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
and	NULL
AP-1	NULL
enhancer	NULL
elements	NULL
.	NULL

J.	NULL
Exp	NULL
Med	NULL
.	NULL

175:637	NULL
.	NULL

Schiile	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
M.	NULL
Evans	NULL
.	NULL

1991	NULL
.	NULL

Cross-coupling	NULL
of	NULL
signal	NULL
trans-duction	NULL
pathways	NULL
:	NULL
zinc	NULL
finger	NULL
meets	NULL
leucine	NULL
zipper	NULL
.	NULL

Trends	NULL
Genet	NULL
.	NULL

7:377	NULL
.	NULL

Felli	NULL
,	NULL
M.P	NULL
.	NULL

,	NULL
A.	NULL
Vacca	NULL
,	NULL
D.	NULL
Meco	NULL
,	NULL
I.	NULL
Screpanti	NULL
,	NULL
A.R	NULL
.	NULL

Farina	NULL
,	NULL
M.	NULL
Maroder	NULL
,	NULL
S.	NULL
Martinotti	NULL
,	NULL
E.	NULL
Petrangeli	NULL
,	NULL
L.	NULL
Frati	NULL
,	NULL
and	NULL
A.	NULL
Gulino	NULL
.	NULL

1991	NULL
.	NULL

Retinoic	NULL
acid-induced	NULL
down-regulation	NULL
of	NULL
the	NULL
interleukin-2	NULL
promoter	NULL
via	NULL
cis-regulatory	NULL
sequences	NULL
containing	NULL
an	NULL
octamer	NULL
motif	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11:4771	NULL
.	NULL

Iwata	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Mukai	NULL
,	NULL
Y.	NULL
Nakai	NULL
,	NULL
and	NULL
R.	NULL
Iseki	NULL
,	NULL
1992	NULL
.	NULL

Retinoic	NULL
acid	NULL
inhibits	NULL
activation-induced	NULL
apoptosis	NULL
in	NULL
T	NULL
cell	NULL
hybridomas	NULL
and	NULL
thymocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

149:3302	NULL
.	NULL

Carding	NULL
,	NULL
S.R	NULL
.	NULL

,	NULL
E.J	NULL
.	NULL

Jenkinson	NULL
,	NULL
R.	NULL
Kingston	NULL
,	NULL
A.C.	NULL
Hayday	NULL
,	NULL
K.	NULL
Bottomly	NULL
,	NULL
and	NULL
J.J	NULL
T.	NULL
Owen	NULL
.	NULL

1989	NULL
.	NULL

Developmental	NULL
control	NULL
of	NULL
lymphokine	NULL
gene	NULL
expression	NULL
in	NULL
fetal	NULL
thymocyte	NULL
during	NULL
T-cell	NULL
ontogeny	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

86:3342	NULL
.	NULL

Toribio	NULL
,	NULL
ML	NULL
.	NULL

,	NULL
J.C.	NULL
Gutierrez-Ramoz	NULL
,	NULL
L.	NULL
Pezzi	NULL
,	NULL
MAR	NULL
.	NULL

Marcos	NULL
,	NULL
and	NULL
A.C.	NULL
Martinez	NULL
.	NULL

1989	NULL
.	NULL

Interleukin	NULL
2-dependent	NULL
autocrine	NULL
proliferation	NULL
in	NULL
T-cell	NULL
development	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

342:82	NULL
.	NULL

Fraser	NULL
,	NULL
J.D	NULL
.	NULL

,	NULL
D.	NULL
Strauss	NULL
,	NULL
and	NULL
A.	NULL
Weiss	NULL
.	NULL

1993	NULL
.	NULL

Signal	NULL
transduc-tion	NULL
events	NULL
leading	NULL
to	NULL
T	NULL
cell	NULL
lymphokine	NULL
gene	NULL
expression	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
.	NULL

14:357	NULL
.	NULL

Ullman	NULL
,	NULL
K.S	NULL
.	NULL

,	NULL
J.P.	NULL
Northrop	NULL
,	NULL
C.L	NULL
.	NULL

Verweij	NULL
,	NULL
and	NULL
G.R	NULL
.	NULL

Crabtree	NULL
.	NULL

1990	NULL
.	NULL

Transmission	NULL
of	NULL
signals	NULL
from	NULL
the	NULL
T	NULL
lymphocyte	NULL
antigen	NULL
receptor	NULL
to	NULL
the	NULL
genes	NULL
responsible	NULL
for	NULL
the	NULL
cell	NULL
proliferation	NULL
and	NULL
immune	NULL
function	NULL
:	NULL
the	NULL
missing	NULL
link	NULL
,	NULL
.	NULL

Anny	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

8:421	NULL
.	NULL

Ullman	NULL
,	NULL
K.S	NULL
.	NULL

,	NULL
W.M	NULL
.	NULL

Flanagan	NULL
,	NULL
C.	NULL
A.	NULL
Edwards	NULL
,	NULL
and	NULL
G.R	NULL
.	NULL

Crabtree	NULL
.	NULL

1991	NULL
.	NULL

Activation	NULL
of	NULL
early	NULL
gene	NULL
expression	NULL
in	NULL
T	NULL
lympho-cytes	NULL
by	NULL
Oct-1	NULL
and	NULL
an	NULL
inducible	NULL
protein	NULL
,	NULL
OAP	NULL
``	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

254:558	NULL
.	NULL

Ullman	NULL
,	NULL
K.S	NULL
.	NULL

,	NULL
J.P.	NULL
Northrop	NULL
,	NULL
A.	NULL
Admon	NULL
,	NULL
and	NULL
G.R	NULL
.	NULL

Crabtree	NULL
.	NULL

1993	NULL
.	NULL

Jun	NULL
family	NULL
members	NULL
are	NULL
controlled	NULL
by	NULL
a	NULL
calcium-regulated	NULL
,	NULL
cyclosporin	NULL
A-sensitive	NULL
signalling	NULL
pathway	NULL
in	NULL
activated	NULL
T	NULL
lym-phocytes	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

7:188	NULL
.	NULL

Kamps	NULL
,	NULL
M.P	NULL
.	NULL

,	NULL
L.	NULL
Corcoran	NULL
,	NULL
J.	NULL
H.	NULL
LeBowitz	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
promoter	NULL
of	NULL
the	NULL
human	NULL
interleukin-2	NULL
gene	NULL
contains	NULL
two	NULL
octamer-binding	NULL
sites	NULL
and	NULL
is	NULL
partially	NULL
activated	NULL
by	NULL
the	NULL
expression	NULL
of	NULL
IL-	NULL
2-2	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10:5464	NULL
.	NULL

Kang	NULL
,	NULL
S.	NULL
,	NULL
W.	NULL
Tsang	NULL
,	NULL
S.	NULL
Doll	NULL
,	NULL
P.	NULL
Scherle	NULL
,	NULL
H.-S.	NULL
Ko	NULL
,	NULL
A.-C.	NULL
Tran	NULL
,	NULL
M.J.	NULL
Lenardo	NULL
,	NULL
and	NULL
L.M	NULL
.	NULL

Staudt	NULL
.	NULL

1992	NULL
.	NULL

Induction	NULL
of	NULL
the	NULL
POU	NULL
1496	NULL
33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
,	NULL
45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49.	NULL
domain	NULL
transcription	NULL
factor	NULL
Oct-2	NULL
during	NULL
T-cell	NULL
activation	NULL
by	NULL
cognate	NULL
antigen	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:3149	NULL
.	NULL

Stern	NULL
,	NULL
S.	NULL
,	NULL
M.	NULL
Tanaka	NULL
,	NULL
and	NULL
W.	NULL
Herr	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Oct-1	NULL
homeodomain	NULL
directs	NULL
formation	NULL
of	NULL
a	NULL
multiprotein-DNA	NULL
complex	NULL
with	NULL
the	NULL
HSV	NULL
transactivator	NULL
VP16	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

341:624	NULL
.	NULL

Tanaka	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
W.	NULL
Herr	NULL
.	NULL

1990	NULL
.	NULL

Differential	NULL
transcriptional	NULL
activation	NULL
by	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
:	NULL
interdependent	NULL
activation	NULL
domains	NULL
induce	NULL
Oct-2	NULL
phosphorylation	NULL
.	NULL

Cell	NULL
.	NULL

60:375	NULL
.	NULL

Siebenlist	NULL
,	NULL
U.	NULL
,	NULL
D.B	NULL
.	NULL

Durand	NULL
,	NULL
P.	NULL
Bressler	NULL
,	NULL
N.J.	NULL
Holbrook	NULL
,	NULL
C.A	NULL
.	NULL

Norris	NULL
,	NULL
M.	NULL
Kamoun	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Kant	NULL
,	NULL
and	NULL
G.R	NULL
.	NULL

Crabtree	NULL
.	NULL

1986	NULL
.	NULL

Promoter	NULL
region	NULL
of	NULL
interleukin-2	NULL
gene	NULL
undergoes	NULL
chromatin	NULL
structure	NULL
changes	NULL
and	NULL
confers	NULL
inducibility	NULL
on	NULL
chloramphenicolace-tyltransferase	NULL
gene	NULL
during	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

6:3042	NULL
.	NULL

Luckow	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
G.	NULL
Schutz	NULL
.	NULL

1987	NULL
.	NULL

CAT	NULL
constructions	NULL
with	NULL
multiple	NULL
unique	NULL
restriction	NULL
sites	NULL
for	NULL
the	NULL
functional	NULL
analysis	NULL
of	NULL
eukaryotic	NULL
promoters	NULL
and	NULL
regulatory	NULL
elements	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
,	NULL
15:5490	NULL
.	NULL

Strihle	NULL
,	NULL
U.	NULL
,	NULL
W.	NULL
Schmid	NULL
,	NULL
and	NULL
G.	NULL
Schutz	NULL
.	NULL

1988	NULL
.	NULL

Synergistic	NULL
action	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
with	NULL
transcription	NULL
factors	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

7:3381	NULL
.	NULL

Petkovic	NULL
,	NULL
M.	NULL
,	NULL
N.J	NULL
.	NULL

Brand	NULL
,	NULL
A.	NULL
Krust	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1987	NULL
.	NULL

A	NULL
human	NULL
retinoic	NULL
acid	NULL
receptor	NULL
which	NULL
belongs	NULL
to	NULL
the	NULL
family	NULL
of	NULL
nuclear	NULL
receptors	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

330:444	NULL
.	NULL

Umesono	NULL
,	NULL
K.	NULL
,	NULL
V.	NULL
Giguere	NULL
,	NULL
C.K	NULL
.	NULL

Christofer	NULL
,	NULL
M.G	NULL
.	NULL

Rosenfeld	NULL
,	NULL
and	NULL
R.M	NULL
.	NULL

Evans	NULL
.	NULL

1988	NULL
.	NULL

Retinoic	NULL
acid	NULL
and	NULL
thyroid	NULL
hormone	NULL
induce	NULL
gene	NULL
expression	NULL
through	NULL
a	NULL
common	NULL
responsive	NULL
element	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

336:262	NULL
.	NULL

Angel	NULL
,	NULL
P.	NULL
,	NULL
M.	NULL
Imagawa	NULL
,	NULL
R.	NULL
Chiu	NULL
,	NULL
B.	NULL
Stein	NULL
,	NULL
R.J.	NULL
Imbra	NULL
,	NULL
H.J	NULL
.	NULL

Rahmsdorf	NULL
,	NULL
C.	NULL
Jonat	NULL
,	NULL
P.	NULL
Herrlich	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1987	NULL
.	NULL

Phorbol	NULL
ester-inducible	NULL
genes	NULL
contain	NULL
a	NULL
common	NULL
cis	NULL
element	NULL
recognized	NULL
by	NULL
a	NULL
TPA-modulated	NULL
trans-acting	NULL
factor	NULL
.	NULL

Cell	NULL
.	NULL

49:729	NULL
.	NULL

Angel	NULL
,	NULL
P.	NULL
,	NULL
K.	NULL
Hattori	NULL
,	NULL
T.	NULL
Smeal	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
jun	NULL
protooncogene	NULL
is	NULL
positively	NULL
autoregulated	NULL
by	NULL
its	NULL
product	NULL
,	NULL
jun/AP-1	NULL
.	NULL

Cell	NULL
.	NULL

55:875	NULL
.	NULL

Chiu	NULL
,	NULL
R.	NULL
,	NULL
P.	NULL
Angel	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1989	NULL
.	NULL

Jun-B	NULL
differs	NULL
in	NULL
its	NULL
biological	NULL
properties	NULL
from	NULL
,	NULL
and	NULL
is	NULL
a	NULL
negative	NULL
regulator	NULL
of	NULL
c-Jun	NULL
.	NULL

Cell	NULL
.	NULL

59:979	NULL
.	NULL

Jenuwein	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
R.	NULL
Muller	NULL
.	NULL

1987	NULL
.	NULL

Structure-function	NULL
analysis	NULL
of	NULL
fos	NULL
protein	NULL
:	NULL
a	NULL
single	NULL
amino	NULL
acid	NULL
change	NULL
activates	NULL
the	NULL
immortalizing	NULL
potential	NULL
of	NULL
v-fos	NULL
.	NULL

Cell	NULL
.	NULL

48:647	NULL
.	NULL

Lucibello	NULL
,	NULL
FC	NULL
.	NULL

,	NULL
C.	NULL
Lowag	NULL
,	NULL
M.	NULL
Neuberg	NULL
,	NULL
and	NULL
R.	NULL
Muller	NULL
.	NULL

1989	NULL
.	NULL

Trans-repression	NULL
of	NULL
the	NULL
mouse	NULL
c-fos	NULL
promoter	NULL
:	NULL
a	NULL
novel	NULL
mechanism	NULL
of	NULL
fos-mediated	NULL
transregulation	NULL
.	NULL

Cell	NULL
.	NULL

59:999	NULL
.	NULL

Queen	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1983	NULL
.	NULL

Immunoglobulin	NULL
gene	NULL
transcription	NULL
is	NULL
activated	NULL
by	NULL
downstream	NULL
sequence	NULL
elements	NULL
.	NULL

Cell	NULL
.	NULL

33:741	NULL
.	NULL

Schreiber	NULL
,	NULL
E.	NULL
,	NULL
K.	NULL
Harshman	NULL
,	NULL
I.	NULL
Kemler	NULL
,	NULL
U.	NULL
Malipiero	NULL
,	NULL
W.	NULL
Schaffner	NULL
,	NULL
and	NULL
A.	NULL
Fontana	NULL
.	NULL

1990	NULL
.	NULL

Astrocytes	NULL
and	NULL
glioblastoma	NULL
cells	NULL
express	NULL
novel	NULL
octamer-DNA	NULL
binding	NULL
proteins	NULL
distinct	NULL
from	NULL
the	NULL
ubiquitous	NULL
Oct-1	NULL
and	NULL
B	NULL
cell	NULL
type	NULL
Oct-2	NULL
proteins	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

18:5495	NULL
.	NULL

Granelli-Piperno	NULL
,	NULL
A.	NULL
,	NULL
P.	NULL
Nolan	NULL
,	NULL
K.	NULL
Inaba	NULL
,	NULL
and	NULL
R.M	NULL
.	NULL

Steinman	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
immunosuppressive	NULL
agents	NULL
on	NULL
the	NULL
induction	NULL
of	NULL
nuclear	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
sites	NULL
on	NULL
the	NULL
interleukin-2	NULL
promoter	NULL
.	NULL

J.	NULL
Exp	NULL
Med	NULL
.	NULL

172:1869	NULL
.	NULL

Rochette-Egly	NULL
,	NULL
C.	NULL
,	NULL
Y.	NULL
Lutz	NULL
,	NULL
M.	NULL
Saunders	NULL
,	NULL
I.	NULL
Scheuer	NULL
,	NULL
M.-P.	NULL
Gaub	NULL
,	NULL
and	NULL
M.	NULL
Chambon	NULL
.	NULL

1991	NULL
.	NULL

Retinoic	NULL
acid	NULL
receptor	NULL
y	NULL
:	NULL
specific	NULL
immunodetection	NULL
and	NULL
phosphorylation	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

115:535	NULL
.	NULL

Quinn	NULL
,	NULL
J.P.	NULL
,	NULL
M.	NULL
Takimoto	NULL
,	NULL
M.	NULL
Iadarola	NULL
,	NULL
N.	NULL
Holbrook	NULL
,	NULL
and	NULL
D.	NULL
Levens	NULL
.	NULL

1989	NULL
.	NULL

Distinct	NULL
factors	NULL
bind	NULL
the	NULL
AP-1	NULL
consensus	NULL
site	NULL
in	NULL
Gibbon	NULL
ape	NULL
leukemia	NULL
virus	NULL
and	NULL
Simian	NULL
virus	NULL
40	NULL
enhancer	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

631737	NULL
.	NULL

IL-2	NULL
Octamer	NULL
Regulation	NULL
by	NULL
Ap-1	NULL
,	NULL
Oct-2	NULL
,	NULL
and	NULL
RAR	NULL
50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

De	NULL
The	NULL
,	NULL
H.	NULL
,	NULL
M.d.M	NULL
.	NULL

Vivanco-Ruiz	NULL
,	NULL
P.	NULL
Tiollais	NULL
,	NULL
H.	NULL
Stunnen-berg	NULL
,	NULL
and	NULL
A.	NULL
Dejean	NULL
.	NULL

1990	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
retinoic	NULL
acid	NULL
responsive	NULL
element	NULL
in	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
B	NULL
gene	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

343177	NULL
.	NULL

Vacca	NULL
,	NULL
A.	NULL
,	NULL
S.	NULL
Martinotti	NULL
,	NULL
I.	NULL
Screpanti	NULL
,	NULL
M.	NULL
Maroder	NULL
,	NULL
M.P	NULL
.	NULL

Felli	NULL
,	NULL
AR	NULL
.	NULL

Farina	NULL
,	NULL
A.	NULL
Gismondi	NULL
,	NULL
A.	NULL
Santoni	NULL
,	NULL
L.	NULL
Frati	NULL
,	NULL
and	NULL
A.	NULL
Gulino	NULL
.	NULL

1990	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
gene	NULL
by	NULL
glucocorticoid	NULL
hormones	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265:8075	NULL
.	NULL

Annweiler	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Miiller-Immergluck	NULL
,	NULL
and	NULL
T.	NULL
Wirth	NULL
.	NULL

1992	NULL
.	NULL

Oct2	NULL
transactivation	NULL
from	NULL
a	NULL
remote	NULL
enhancer	NULL
position	NULL
requires	NULL
a	NULL
B-cell-restricted	NULL
activity	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:3107	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
V.E	NULL
.	NULL

Valge-Archer	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1992	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
AP-1	NULL
sites	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

148:1240	NULL
.	NULL

Farina	NULL
,	NULL
A.R	NULL
.	NULL

,	NULL
T.	NULL
Davis-Smith	NULL
,	NULL
K.	NULL
Gardner	NULL
,	NULL
and	NULL
D.	NULL
Levens	NULL
.	NULL

1993	NULL
.	NULL

An	NULL
early	NULL
response	NULL
of	NULL
an	NULL
AP-1-junD	NULL
complex	NULL
driving	NULL
T	NULL
cell	NULL
ac-tivation	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:26466	NULL
.	NULL

Leid	NULL
,	NULL
M.	NULL
,	NULL
P.	NULL
Kastner	NULL
,	NULL
R.	NULL
Lyons	NULL
,	NULL
H.	NULL
Nakshatri	NULL
,	NULL
M.	NULL
Saunders	NULL
,	NULL
T.	NULL
Chen	NULL
,	NULL
J.Y	NULL
.	NULL

Staub	NULL
,	NULL
A.	NULL
Garnier	NULL
,	NULL
J.M	NULL
.	NULL

Mader	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1992	NULL
.	NULL

Purification	NULL
,	NULL
cloning	NULL
and	NULL
RXR	NULL
identity	NULL
of	NULL
the	NULL
HeLa	NULL
cell	NULL
factor	NULL
with	NULL
which	NULL
RAR	NULL
or	NULL
TR	NULL
heterodimerizes	NULL
to	NULL
bind	NULL
target	NULL
sequences	NULL
efficiently	NULL
.	NULL

Cell	NULL
.	NULL

68:377	NULL
.	NULL

Yu	NULL
,	NULL
VC	NULL
.	NULL

,	NULL
C.	NULL
Delsert	NULL
,	NULL
B.	NULL
Andersen	NULL
,	NULL
J.M	NULL
.	NULL

Holloway	NULL
,	NULL
OV	NULL
.	NULL

Devary	NULL
,	NULL
A.M.	NULL
Naar	NULL
,	NULL
SY	NULL
.	NULL

Kim	NULL
,	NULL
J.M	NULL
.	NULL

Routin	NULL
,	NULL
C.K	NULL
.	NULL

Glass	NULL
,	NULL
and	NULL
M.G	NULL
.	NULL

Rosenfeld	NULL
.	NULL

1991	NULL
.	NULL

RXRbeta	NULL
:	NULL
a	NULL
coregulator	NULL
that	NULL
enhances	NULL
binding	NULL
of	NULL
retinoic	NULL
acid	NULL
,	NULL
thyroid	NULL
hormone	NULL
,	NULL
and	NULL
vitamin	NULL
D	NULL
receptors	NULL
to	NULL
their	NULL
cognate	NULL
response	NULL
elements	NULL
.	NULL

Cell	NULL
.	NULL

67:1251	NULL
.	NULL

Luo	NULL
,	NULL
Y.	NULL
,	NULL
H.	NULL
Fuji	NULL
,	NULL
T.	NULL
Gerster	NULL
,	NULL
and	NULL
R.G	NULL
.	NULL

Roeder	NULL
.	NULL

1992	NULL
.	NULL

A	NULL
novel	NULL
B	NULL
cell-derived	NULL
coactivator	NULL
potentiates	NULL
the	NULL
activation	NULL
of	NULL
immunoglobulin	NULL
promoters	NULL
by	NULL
octamer-binding	NULL
transcription	NULL
factors	NULL
.	NULL

Cell	NULL
.	NULL

71:231	NULL
.	NULL

Scholer	NULL
,	NULL
H.R	NULL
.	NULL

,	NULL
T.	NULL
Ciesiolka	NULL
,	NULL
and	NULL
P.	NULL
Gruss	NULL
.	NULL

1991	NULL
.	NULL

A	NULL
nexus	NULL
between	NULL
Oct-4	NULL
and	NULL
E1A	NULL
:	NULL
implications	NULL
for	NULL
gene	NULL
regulation	NULL
in	NULL
embryonic	NULL
stem	NULL
cells	NULL
,	NULL
Cell	NULL
.	NULL

66:291	NULL
.	NULL

Boise	NULL
,	NULL
L.	NULL
H.	NULL
,	NULL
B.	NULL
Petryniak	NULL
,	NULL
X.	NULL
Mao	NULL
,	NULL
C.H	NULL
.	NULL

June	NULL
,	NULL
C.-Y	NULL
.	NULL

Wang	NULL
,	NULL
T.	NULL
Lindsten	NULL
,	NULL
R.	NULL
Bravo	NULL
,	NULL
K.	NULL
Kovary	NULL
,	NULL
J.M	NULL
.	NULL

Leiden	NULL
,	NULL
and	NULL
C.B	NULL
.	NULL

Thompson	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
NFAT-1	NULL
DNA	NULL
binding	NULL
complex	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
contains	NULL
Fra-1	NULL
and	NULL
JunB	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:1911	NULL
.	NULL

Northrop	NULL
,	NULL
P.J	NULL
.	NULL

,	NULL
K.S	NULL
.	NULL

Ullman	NULL
,	NULL
and	NULL
G.R	NULL
.	NULL

Crabtree	NULL
.	NULL

1993	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
nuclear	NULL
and	NULL
cytoplasmic	NULL
components	NULL
of	NULL
the	NULL
lymphoid-specific	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NF-AT	NULL
)	NULL
complex	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:2917	NULL
.	NULL

Thompson	NULL
,	NULL
C.B	NULL
.	NULL

,	NULL
C.-Y	NULL
.	NULL

Wang	NULL
,	NULL
I.-C.	NULL
Ho	NULL
,	NULL
P.R	NULL
.	NULL

Bohjanen	NULL
,	NULL
B	NULL
.	NULL

1497	NULL
de	NULL
Grazia	NULL
et	NULL
al	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

67	NULL
.	NULL

68	NULL
.	NULL

69	NULL
.	NULL

70	NULL
.	NULL

Petryniak	NULL
,	NULL
C.H	NULL
.	NULL

June	NULL
,	NULL
S.	NULL
Miesfeldt	NULL
,	NULL
L.	NULL
Zhang	NULL
,	NULL
G.J	NULL
.	NULL

Nabel	NULL
,	NULL
B.	NULL
Karpinski	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1992.	NULL
cis-acting	NULL
sequences	NULL
required	NULL
for	NULL
inducible	NULL
interleukin-2	NULL
enhancer	NULL
function	NULL
bind	NULL
a	NULL
novel	NULL
Ets-related	NULL
protein	NULL
,	NULL
EIF1	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:1043	NULL
.	NULL

Lipkin	NULL
,	NULL
S.M	NULL
.	NULL

,	NULL
C.A	NULL
.	NULL

Nelson	NULL
,	NULL
C.K	NULL
.	NULL

Glass	NULL
,	NULL
and	NULL
M.G	NULL
.	NULL

Rosenfeld	NULL
.	NULL

1992	NULL
.	NULL

A	NULL
negative	NULL
retinoic	NULL
acid	NULL
response	NULL
element	NULL
in	NULL
the	NULL
rat	NULL
oxy-tocin	NULL
promoter	NULL
restricts	NULL
transcriptional	NULL
stimulation	NULL
by	NULL
heterologous	NULL
transactivation	NULL
domain	NULL
.	NULL

Proc	NULL
Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

89:1209	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
PG	NULL
.	NULL

MacCaffrey	NULL
,	NULL
V.E	NULL
.	NULL

Valge-Archer	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1992	NULL
.	NULL

Nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
contains	NULL
fos	NULL
and	NULL
jun	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

356:801	NULL
.	NULL

Kutoh	NULL
,	NULL
E.	NULL
,	NULL
P.-E.	NULL
Stromstedt	NULL
,	NULL
and	NULL
L.	NULL
Poellinger	NULL
.	NULL

1992	NULL
.	NULL

Functional	NULL
interference	NULL
between	NULL
the	NULL
ubiquitous	NULL
and	NULL
constitutive	NULL
octamer	NULL
transcription	NULL
factor	NULL
1	NULL
(	NULL
OTF-1	NULL
)	NULL
and	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
by	NULL
direct	NULL
protein-protein	NULL
interaction	NULL
involving	NULL
the	NULL
homeo	NULL
subdomain	NULL
of	NULL
OTF-1	NULL
,	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:4960	NULL
.	NULL

Bruggemeier	NULL
,	NULL
U.	NULL
,	NULL
M.	NULL
Kalff	NULL
,	NULL
S.	NULL
Franke	NULL
,	NULL
C.	NULL
Sceidereit	NULL
,	NULL
and	NULL
M.	NULL
Beato	NULL
.	NULL

1991	NULL
.	NULL

Ubiquitous	NULL
transcription	NULL
factor	NULL
OTF-1	NULL
mediates	NULL
induction	NULL
of	NULL
the	NULL
MMTV	NULL
promoter	NULL
through	NULL
synergistic	NULL
interaction	NULL
with	NULL
hormone	NULL
receptors	NULL
.	NULL

Cell	NULL
.	NULL

64:565	NULL
.	NULL

Lanigan	NULL
,	NULL
TM	NULL
.	NULL

,	NULL
L.A.	NULL
Tverberg	NULL
,	NULL
and	NULL
A.F	NULL
.	NULL

Russo	NULL
.	NULL

1993	NULL
.	NULL

Retinoic	NULL
acid	NULL
repression	NULL
of	NULL
cell-specific	NULL
helix-loop-helix	NULL
octamer	NULL
activation	NULL
of	NULL
the	NULL
calcitonin/calcitonin	NULL
gene-related	NULL
peptide	NULL
enhancer	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:6079	NULL
.	NULL

Screpanti	NULL
,	NULL
I.	NULL
,	NULL
D.	NULL
Meco	NULL
,	NULL
S.	NULL
Scarpa	NULL
,	NULL
S.	NULL
Morrone	NULL
,	NULL
L.	NULL
Frati	NULL
,	NULL
A.	NULL
Gulino	NULL
,	NULL
and	NULL
A.	NULL
Modesti	NULL
.	NULL

1992	NULL
,	NULL
Neuromodulatory	NULL
loop	NULL
mediated	NULL
by	NULL
nerve	NULL
growth	NULL
factor	NULL
and	NULL
interleukin-6	NULL
in	NULL
thymic	NULL
stromal	NULL
cell	NULL
cultures	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

89:3209	NULL
.	NULL

Meco	NULL
,	NULL
D.	NULL
,	NULL
S.	NULL
Scarpa	NULL
,	NULL
M.	NULL
Napolitano	NULL
,	NULL
M.	NULL
Maroder	NULL
,	NULL
D.	NULL
Bellavia	NULL
,	NULL
R.	NULL
De	NULL
Maria	NULL
,	NULL
M.	NULL
Ragano-Caracciolo	NULL
,	NULL
L.	NULL
Frati	NULL
,	NULL
A.	NULL
Modesti	NULL
,	NULL
A.	NULL
Gulino	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
.	NULL

Modulation	NULL
of	NULL
fibronectin	NULL
and	NULL
thymic	NULL
stromal	NULL
cell-dependent	NULL
thymocyte	NULL
maturation	NULL
by	NULL
retinoic	NULL
acid	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

153:73	NULL
.	NULL

Kang	NULL
,	NULL
S.-M.	NULL
,	NULL
B.	NULL
Beverly	NULL
,	NULL
A.-C.	NULL
Tran	NULL
,	NULL
K.	NULL
Brorson	NULL
,	NULL
RH	NULL
.	NULL

Schwartz	NULL
,	NULL
and	NULL
M.	NULL
Lenardo	NULL
.	NULL

1992	NULL
.	NULL

Transactivation	NULL
by	NULL
AP-1	NULL
is	NULL
a	NULL
molecular	NULL
target	NULL
of	NULL
T	NULL
cell	NULL
clonal	NULL
anergy	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

257:1134	NULL
.	NULL

Chen	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
EV	NULL
.	NULL

Rothenberg	NULL
.	NULL

1993	NULL
.	NULL

Molecular	NULL
basis	NULL
for	NULL
developmental	NULL
changes	NULL
in	NULL
interleukin-2	NULL
gene	NULL
inducibility	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:228	NULL
.	NULL

